<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pantoprazole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pantoprazole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pantoprazole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10947" href="/d/html/10947.html" rel="external">see "Pantoprazole: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12677" href="/d/html/12677.html" rel="external">see "Pantoprazole: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F206239"><span class="drugH1">Brand Names: US</span>
<ul>
<li>First Pantoprazole;</li>
<li>Protonix</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867837"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Pantoprazole;</li>
<li>AG-Pantoprazole Sodium;</li>
<li>APO-Pantoprazole;</li>
<li>Auro-Pantoprazole;</li>
<li>BIO-Pantoprazole;</li>
<li>JAMP-Pantoprazole;</li>
<li>JAMP-Pantoprazole Sodium;</li>
<li>M-Pantoprazole;</li>
<li>Mar-Pantoprazole;</li>
<li>MINT-Pantoprazole;</li>
<li>MYLAN-Pantoprazole T;</li>
<li>NRA-Pantoprazole;</li>
<li>Pantoloc;</li>
<li>Pantoprazole;</li>
<li>Pantoprazole T;</li>
<li>Pantoprazole-20;</li>
<li>Pantoprazole-40;</li>
<li>PMS-Pantoprazole;</li>
<li>Priva-Pantoprazole [DSC];</li>
<li>RIVA-Pantoprazole;</li>
<li>SANDOZ Pantoprazole;</li>
<li>TARO-Pantoprazole;</li>
<li>Tecta;</li>
<li>TEVA-Pantoprazole;</li>
<li>TEVA-Pantoprazole Magnesium</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F206284"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Proton Pump Inhibitor;</li>
<li>
                        Substituted Benzimidazole</li></ul></div>
<div class="block doa drugH1Div" id="F206244"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations</b>: Avoid coadministration with other antisecretory agents due to decreased acid-inhibitory effects. If another antisecretory agent is needed, allow a sufficient time interval between administration (ie, morning pantoprazole and bedtime H<sub>2</sub>RA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419381','lexi-content-ref-Wolfe.2020','lexi-content-ref-10868896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419381','lexi-content-ref-Wolfe.2020','lexi-content-ref-10868896'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9e2fd80-308d-4eb0-a497-00b0397cb8b3">Aspiration prophylaxis in patients undergoing anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspiration prophylaxis in patients undergoing anesthesia (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be considered in patients at high risk for aspiration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28045707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28045707'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 mg given the night before surgery and 40 mg given the morning of surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21655020','lexi-content-ref-22289674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21655020','lexi-content-ref-22289674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 40 mg as a single dose 1 hour prior to induction anesthesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14570652','lexi-content-ref-18754096','lexi-content-ref-22289674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14570652','lexi-content-ref-18754096','lexi-content-ref-22289674'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60677fdf-855d-4121-a2fd-089025faf2ea">Barrett esophagus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Barrett esophagus (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 mg once daily; may increase the dose to 40 mg twice daily if needed to eliminate gastroesophageal reflux disease (GERD) symptoms or heal reflux esophagitis. Long-term maintenance therapy is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26526079','lexi-content-ref-26790552','lexi-content-ref-Spechler2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26526079','lexi-content-ref-26790552','lexi-content-ref-Spechler2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4d2394bf-599a-4605-a6c3-07d160c2d0c7">Dyspepsia, functional</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyspepsia, functional (idiopathic or non-ulcer) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients who test negative for <i>Helicobacter pylori</i> infection or have persistent symptoms following <i>H. pylori</i> eradication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28631728','lexi-content-ref-Longstreth.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28631728','lexi-content-ref-Longstreth.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 to 40 mg once daily for a 4- to 8-week trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26811504','lexi-content-ref-28271513','lexi-content-ref-18534050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26811504','lexi-content-ref-28271513','lexi-content-ref-18534050'])">Ref</a></span>); can be continued for a longer duration in patients with symptom improvement. Some experts recommend attempting to discontinue every 6 to 12 months to minimize the long-term risk of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Longstreth.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Longstreth.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7eb41f5-ab77-43d2-b32d-436b6b436e7f">Eosinophilic esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic esophagitis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 mg twice daily for an 8-week trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32677040','lexi-content-ref-26247167','lexi-content-ref-24117619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32677040','lexi-content-ref-26247167','lexi-content-ref-24117619'])">Ref</a></span>). Once 8-week trial is complete and remission is achieved, the dose may be gradually lowered to an individualized maintenance level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32677040']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32677040'])">Ref</a></span>). Some experts initiate with once-daily dosing and increase to twice-daily dosing after 4 weeks if symptoms fail to improve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bonis.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bonis.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af13b8bc-31d9-4d53-ade6-d0f129e2f0f1">Gastroesophageal reflux disease, erosive or nonerosive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease, erosive or nonerosive: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Mild/intermittent disease (&lt;2 episodes/week) and no evidence of erosive esophagitis: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts reserve proton pump inhibitors (PPIs) for patients who have residual acid reflux symptoms despite twice-daily H<sub>2</sub>RA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 20 mg once daily, can increase to 40 mg once daily after 4 to 8 weeks if necessary. Discontinue once asymptomatic for 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Severe and/or frequent symptoms (≥2 episodes/week), and/or erosive esophagitis:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 40 mg once daily; once symptoms are controlled, continue for at least 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2020','lexi-content-ref-BCMH.2015','lexi-content-ref-10868896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2020','lexi-content-ref-BCMH.2015','lexi-content-ref-10868896'])">Ref</a></span>). Subsequently, patients without erosive esophagitis or Barrett esophagus can taper to the lowest dose necessary to control symptoms (and/or switch to an H<sub>2</sub>RA blocker), then discontinue acid suppression once asymptomatic. Patients with erosive esophagitis or Barrett esophagus should continue long-term maintenance therapy with 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2020','lexi-content-ref-12095478','lexi-content-ref-Spechler2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2020','lexi-content-ref-12095478','lexi-content-ref-Spechler2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV (in patients unable to receive oral medications):</b> 40 mg once daily, then switch to oral when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10710049']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10710049'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Residual symptoms despite 40 mg once daily therapy</i>: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Referral to a specialist is recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Options include splitting the dose to 20 mg twice daily, increasing the dose to 40 mg twice daily, or switching to another PPI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419381','lexi-content-ref-Fass.2019','lexi-content-ref-19373423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419381','lexi-content-ref-Fass.2019','lexi-content-ref-19373423'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Helicobacter pylori </b></i>
<b>eradication (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 mg or 80 mg twice daily as part of an appropriate combination regimen with antibiotics. Dose depends on the selected regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-Crowe.2020','lexi-content-ref-27102658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-Crowe.2020','lexi-content-ref-27102658'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2fb2a31-e99b-4da1-8e12-14220432720a">Nonsteroidal anti-inflammatory drug–induced ulcers, primary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonsteroidal anti-inflammatory drug (including aspirin)–induced ulcers, primary prevention (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For select patients at moderate or high risk for GI toxicity. These include patients with a history of GI ulcer, on dual antiplatelet therapy (eg, aspirin plus a P2Y<sub>12</sub> inhibitor), on concurrent anticoagulant therapy, or with multiple additional risk factors (eg, corticosteroid use, high nonsteroidal anti-inflammatory drug [NSAID] dose, <i>H. pylori</i> infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feldman.2019.1','lexi-content-ref-Holmes.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feldman.2019.1','lexi-content-ref-Holmes.2019'])">Ref</a></span>). For patients on dual antiplatelet therapy, some experts reserve prophylaxis for those with additional risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21060077','lexi-content-ref-28886621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21060077','lexi-content-ref-28886621'])">Ref</a></span>). If present, <i>H. pylori</i> infection should be treated first (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19240698','lexi-content-ref-Feldman.2019.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19240698','lexi-content-ref-Feldman.2019.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 to 40 mg once daily for the duration of high-risk NSAID use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10975769','lexi-content-ref-19761935','lexi-content-ref-16817839','lexi-content-ref-19350116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10975769','lexi-content-ref-19761935','lexi-content-ref-16817839','lexi-content-ref-19350116'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a452940-c4b2-4e83-b889-1684a62dda20">Peptic ulcer disease, treatment and secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peptic ulcer disease, treatment and secondary prevention (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: For patients on NSAIDs (including aspirin), the NSAID should be discontinued, if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feldman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feldman.2019'])">Ref</a></span>). If present, <i>H. pylori</i> infection should be treated first; uncomplicated <i>H. pylori–</i>associated ulcers may not need PPI treatment beyond that included in the eradication regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vakil.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vakil.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uncomplicated ulcer: </i>
<b>Oral:</b> 40 mg once daily. Duration depends on the size, location, and cause of ulcer and ranges from 4 to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7781461','lexi-content-ref-8527617','lexi-content-ref-9882033','lexi-content-ref-7766739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7781461','lexi-content-ref-8527617','lexi-content-ref-9882033','lexi-content-ref-7766739'])">Ref</a></span>). In patients with refractory or recurrent disease, may increase the dose to 40 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vakil.2020a','lexi-content-ref-Vakil.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vakil.2020a','lexi-content-ref-Vakil.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Complicated </i>
<i>ulcer (perforation, penetration, or gastric outlet obstruction): </i>
<b>Oral, IV:</b> 40 mg twice daily for 4 weeks, followed by 40 mg once daily. Duration depends on the location and etiology of ulcer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vakil.2020b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vakil.2020b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ddad78db-4422-47a9-8299-1c11f40d1828">Stress ulcer prophylaxis in select critically ill patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress ulcer prophylaxis in select critically ill patients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use in critically ill patients with risk factors for GI bleeding (eg, coagulopathy, mechanical ventilation for &gt;48 hours, traumatic brain injury, history of GI ulceration or bleeding within past year, extensive burns) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28459708','lexi-content-ref-30354950','lexi-content-ref-27635481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28459708','lexi-content-ref-30354950','lexi-content-ref-27635481'])">Ref</a></span>). Discontinue prophylaxis once risk factors have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral or via nasogastric tube:</b> 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16443807','lexi-content-ref-19561850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16443807','lexi-content-ref-19561850'])">Ref</a></span>). Discontinue prophylaxis once risk factors have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11220b85-ee52-4706-bb7b-6bdeebb826e9">Upper GI bleed, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Upper GI bleed, acute (unknown etiology or peptic ulcer hemorrhage) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pre-endoscopy: Note:</b> Optimal PPI therapy is uncertain. For patients with suspected active upper GI bleed, some experts suggest initiating high-dose IV PPI with continuous or intermittent dosing prior to endoscopy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377'])">Ref</a></span>). Where IV PPIs are unavailable, high-dose oral PPI therapy is a reasonable alternative (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33567467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33567467'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion:</i>
<b>IV:</b> 80 mg bolus, followed by 8 mg/hour until endoscopy with subsequent dosing based on endoscopic findings (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-33567467','lexi-content-ref-35898254','lexi-content-ref-34995368','lexi-content-ref-17014584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-33567467','lexi-content-ref-35898254','lexi-content-ref-34995368','lexi-content-ref-17014584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent dosing:</i>
<b>IV:</b> 80 mg once (active bleeding) or 40 mg once (no evidence of active bleeding); if endoscopy is not performed within 12 hours, begin 40 mg every 12 hours until endoscopy. Subsequent dosing is based on endoscopic findings (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377','lexi-content-ref-34376087','lexi-content-ref-33567467','lexi-content-ref-35898254','lexi-content-ref-35135340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377','lexi-content-ref-34376087','lexi-content-ref-33567467','lexi-content-ref-35898254','lexi-content-ref-35135340'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (alternative route):</b> 40 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33567467','lexi-content-ref-17014584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33567467','lexi-content-ref-17014584'])">Ref</a></span>). <b>Note:</b> For select patients at low risk for rebleeding (ie, GBS of 0 to 1, clinically stable, timely access to medical care) who are to receive outpatient endoscopy, some experts use 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Saltzman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Saltzman.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Post-endoscopy: Note: </b>Treatment should address the underlying cause of the bleed. In patients with bleeding peptic ulcers, continue PPI therapy and direct further treatment at healing the ulcers and eliminating precipitating factors (eg, <i>H. pylori</i>, NSAIDs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377','lexi-content-ref-33567467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377','lexi-content-ref-33567467'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Peptic ulcer with high-risk stigmata of recent hemorrhage (eg, active bleed, visible vessel, adherent clot):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Continuous infusion:</i>
<b>IV:</b> 80 mg bolus, followed by 8 mg/hour; if patient received 80 mg bolus prior to endoscopy, may omit bolus dose. Continue for ≥72 hours, then transition to high-dose oral maintenance therapy when able to tolerate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-19686407','lexi-content-ref-33567467','lexi-content-ref-35898254','lexi-content-ref-22550833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-19686407','lexi-content-ref-33567467','lexi-content-ref-35898254','lexi-content-ref-22550833'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Intermittent dosing (alternative administration):</i>
<b>IV:</b> 80 mg bolus once, then 40 mg every 12 hours; if 80 mg bolus was received prior to endoscopy, may omit bolus dose. Continue for ≥72 hours, then transition to high-dose oral maintenance therapy when able to tolerate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-19686407','lexi-content-ref-33567467','lexi-content-ref-35898254','lexi-content-ref-34889253','lexi-content-ref-35135340','lexi-content-ref-22550833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-19686407','lexi-content-ref-33567467','lexi-content-ref-35898254','lexi-content-ref-34889253','lexi-content-ref-35135340','lexi-content-ref-22550833'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance therapy:</i>
<b>Oral:</b> 40 mg twice daily for 14 days, followed by 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-33567467','lexi-content-ref-Saltzman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-33567467','lexi-content-ref-Saltzman.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration: </i>The total duration of treatment depends on size, location, and cause of the ulcer, and ranges from 4 to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22310222','lexi-content-ref-20083829','lexi-content-ref-31634917','lexi-content-ref-Vakil.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22310222','lexi-content-ref-20083829','lexi-content-ref-31634917','lexi-content-ref-Vakil.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Peptic ulcer with clean base or flat pigmented spot: Note:</b> May transition to an oral PPI immediately after endoscopy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance therapy:</i>
<b>Oral:</b> 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22310222','lexi-content-ref-33929377','lexi-content-ref-30910853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22310222','lexi-content-ref-33929377','lexi-content-ref-30910853'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration: </i>The total duration of treatment depends on size, location, and cause of the ulcer, and ranges from 4 to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22310222','lexi-content-ref-20083829','lexi-content-ref-31634917','lexi-content-ref-Vakil.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22310222','lexi-content-ref-20083829','lexi-content-ref-31634917','lexi-content-ref-Vakil.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a8380a3f-effc-4362-8570-7449b4c89d7a">Zollinger-Ellison syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Zollinger-Ellison syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 80 mg twice daily; if needed, may titrate upward early in therapy to a maximum of 240 mg/day (as either 80 mg three times daily or 120 mg twice daily); once acid output has been controlled, gradual dose reductions are usually possible; reported maintenance dosage range: 40 to 200 mg/day (mean: 116 mg/day); daily doses ≥80 mg are usually given in 2 to 3 divided doses; continue therapy as long as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bergsland.2020','lexi-content-ref-16423003','lexi-content-ref-12070410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bergsland.2020','lexi-content-ref-16423003','lexi-content-ref-12070410'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (when oral administration is not possible):</b> Initial: 80 mg every 8 to 12 hours; doses up to 240 mg/day (given as 120 mg every 12 hours or 80 mg every 8 hours) have been used for a limited period of time (up to 6 days); switch to oral administration when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10734021','lexi-content-ref-11774936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10734021','lexi-content-ref-11774936'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Discontinuation of therapy:</i></b> In patients who have received continuous therapy for &gt;6 months, some experts gradually taper therapy until discontinuation to avoid worsening or rebound symptoms. There is no single agreed upon discontinuation strategy. If the patient is receiving 40 mg once or twice daily, some experts decrease the dose by 50% every week. For patients receiving twice-daily dosing, the first dose reduction can be achieved by decreasing to once-daily AM dosing. Once patients are on the lowest dose for 1 week, discontinue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wolfe.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wolfe.2020'])">Ref</a></span>). An alternative strategy is to decrease the dose by 50% over 2 to 4 weeks, then discontinue. If the patient is already on the lowest possible dose, alternate-day therapy may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29767318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29767318'])">Ref</a></span>). In addition, as-needed therapy with an H<sub>2</sub>RA or an antacid can be used during the taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25192903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25192903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991232"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: </b>Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8827397','lexi-content-ref-8180291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8827397','lexi-content-ref-8180291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed (~2%): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9623552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9623552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988461"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; doses &gt;40 mg daily have not been evaluated.</p></div>
<div class="block doe drugH1Div" id="F206245"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Avoid scheduled use for &gt;8 weeks unless given for high-risk patients (eg, oral corticosteroid or chronic nonsteroidal anti-inflammatory drug use), patients with erosive esophagitis, Barrett esophagitis, or a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H<sub>2</sub> blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F5707304"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12677" href="/d/html/12677.html" rel="external">see "Pantoprazole: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Dosing should be based on lean body weight in obese patients; pharmacokinetic studies suggest that obese children ≥6 years and adolescents have higher exposures and slower drug clearance compared to nonobese patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29389444','lexi-content-ref-30257076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29389444','lexi-content-ref-30257076'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47b1179c-f245-4f41-8b13-a8d3a1021a5f">Gastric acid suppression; oral therapy not appropriate or tolerated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric acid suppression; oral therapy not appropriate or tolerated:</b> Limited data available; dosing regimens variable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Dosing based on pharmacokinetic data from 39 pediatric patients (age range: 10 days to 16 years) which has shown doses within this range produce similar AUC as adult patients with comparable dosing; efficacy was not evaluated in either trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18664620','lexi-content-ref-19173681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18664620','lexi-content-ref-19173681'])">Ref</a></span>). Parenteral therapy should be discontinued as soon as the patient tolerates oral therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i>: Children ≥2 years and Adolescents: IV: 0.8 or 1.6 mg/kg once daily; maximum single dose: 80 mg; dosing from a single-dose pharmacokinetic study in 18 patients (age range: 2 to 14 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18664620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18664620'])">Ref</a></span>). In a BSA-directed dosing trial,(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19173681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19173681'])">Ref</a></span>) the final median dose when standardized to weight was 1.1 mg/kg/day (range: 0.5 to 4.6 mg/kg/day; <b>Note:</b> The 4.6 mg/kg/day dose was a prescribing error; however, the patient experienced no adverse consequences due to high dose). Additionally, some clinicians have used 1 to 2 mg/kg/day in single or divided doses. <b>Note:</b> In a very small trial (n=8), a median dose of 1.1 mg/kg/dose (0.9 to 2.5 mg/kg/dose) produced similar AUC values as adults, but only produced a definable response (gastric pH &gt;4) in one patient; in the remaining seven patients, the mean percentage of time with intragastric pH ≥4 was 7.4% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Petterson.2005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Petterson.2005'])">Ref</a></span>); the pharmacodynamic profile needs further defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19173681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19173681'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BSA-directed dosing</i>: Infants, Children, and Adolescents: IV: 40 mg/1.73 m<sup>2</sup>/day; if inadequate response (eg, continued symptoms or target gastric pH not achieved), may titrate up to a maximum dose of 80 mg/1.73 m<sup>2</sup>/day; dosing based on multidose pharmacokinetic analysis; in the final analysis, the median reported dose was 41.8 mg/1.73 m<sup>2</sup>/day (range: 19.9 to 140.6 mg/1.73 m<sup>2</sup>/day; <b>Note:</b> The 140.6 mg/1.73 m<sup>2</sup>/day dose was a prescribing error; however, the patient experienced no adverse consequences due to high dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19173681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19173681'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5e4b52c-2ae7-4d5e-bc41-9d176e2d94e2">Gastroesophageal reflux disease, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease (GERD), symptomatic:</b> Limited data available: <b>Note: </b>Guidelines recommend a 4- to 8-week treatment course; if improvement seen after 4 to 8 weeks, consider possible wean; if no response after 4 to 8 weeks, reevaluate diagnosis and consider referral to pediatric GI specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470322'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 1 to 2 mg/kg/day once daily; maximum daily dose: 40 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470322'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab55d7c4-5b3e-44b8-b9fe-7c8c84dff187">Erosive esophagitis associated with gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erosive esophagitis associated with gastroesophageal reflux disease (GERD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 5 years: Limited data available: Oral: 0.3, 0.6, or 1.2 mg/kg/day once daily for 8 weeks was used in a dose-finding study of 60 patients with histologic or erosive esophagitis. High-dose treatment (1.2 mg/kg/day) was administered as a fixed dose of either: 15 mg for 1-year-olds <b>or</b> 20 mg for 2- to 5-year-olds. Patients with erosive esophagitis (n=4) received either 0.6 or 1.2 mg/kg/day. All patients had symptomatic improvement and patients with erosive esophagitis were healed by week 8; no dose response relationship was demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20522615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20522615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">≥15 to &lt;40 kg: Oral: 20 mg once daily for up to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: Oral: 40 mg once daily for up to 8 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Oral: Based on experience in adults, some experts recommend a step-down approach in order to avoid worsening or rebound symptoms. One recommendation is to decrease the dose by 50% over 2 to 4 weeks. If the patient is already on the lowest possible dose, alternate day therapy may be considered. If symptoms worsen during treatment or after discontinuation, patient should be reevaluated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29767318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29767318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51196596"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Children ≥5 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to severe impairment:</b> There are no pediatric-specific recommendations; based on experience in adult patients, no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8827397','lexi-content-ref-8180291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8827397','lexi-content-ref-8180291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent:</b> Poorly dialyzed (~2%): There are no pediatric-specific recommendations for dosing in patients receiving hemodialysis; based on experience in adult patients, no supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9623552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9623552'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51196597"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment suggested in some cases.</p></div>
<div class="block arsc drugH1Div" id="F55161134"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cutaneous and systemic lupus erythematosus</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous lupus erythematosus</b>, most often subacute cutaneous lupus erythematosus (SCLE), has been reported with use of proton pump inhibitors (PPIs), including pantoprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27398293','lexi-content-ref-23548825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27398293','lexi-content-ref-23548825'])">Ref</a></span>). SCLE is reversible (resolution ~3 months following discontinuation [range: 4 weeks to 8 months]), and cross-reactivity between PPIs has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24547721'])">Ref</a></span>). SCLE may present as a widespread skin rash which may include bullous lesions and focal skin necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24547721'])">Ref</a></span>). In addition, systemic lupus erythematosus (SLE) secondary to PPIs may occur, although less often as compared to SCLE. Presentation often includes rash, however, arthralgia or cytopenia may also occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic. SCLE is typically associated with positive antinuclear antibodies (ANA), anti-Ro/SSA and anti-La/SSB antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23548825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23548825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied.</p>
<p style="text-indent:-2em;margin-left:6em;">Cutaneous lupus erythematosus: ~8 months following treatment initiation (range: 3 days to 3.5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18176768','lexi-content-ref-32639541','lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18176768','lexi-content-ref-32639541','lexi-content-ref-24547721'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Systemic lupus erythematosus: According to the manufacturer, may occur within days to years after initiating treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history or family history of SCLE, especially secondary to PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27398293','lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27398293','lexi-content-ref-24547721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for SCLE (eg, female of childbearing age, periods of female hormone changes, prior history of drug allergies, sun-reactive skin, exposure to UV radiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27398293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27398293'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Enteric infections</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of proton pump inhibitors (PPIs), including pantoprazole, may increase risk of enteric infections, including <b>gastroenteritis</b> and <b>
<i>Clostridioides difficile </i>associated diarrhea </b>(CDAD) in adults and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16651285','lexi-content-ref-25112692','lexi-content-ref-20047577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16651285','lexi-content-ref-25112692','lexi-content-ref-20047577'])">Ref</a></span>); however, data are conflicting, especially with regards to CDAD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31378636','lexi-content-ref-31152740','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31378636','lexi-content-ref-31152740','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-28054368'])">Ref</a></span>). <b>Diarrhea</b>, which may be a result of enteric infection, is the most common adverse reaction secondary to long-term PPI use and often results in treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365243'])">Ref</a></span>). Consider CDAD diagnosis in patients with persistent diarrhea that does not improve, especially in hospitalized patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28054368'])">Ref</a></span>); related to the pharmacologic action. The increase in gastric pH secondary to PPI administration leads to changes in intestinal microbial environment which may allow for intestinal germination and growth of <i>C. difficile </i>spores as well as colonization by other bacteria responsible for enteric infections (eg, <i>Salmonella</i>, <i>Campylobacter</i>, <i>Shigella</i>, norovirus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32718584','lexi-content-ref-28325163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32718584','lexi-content-ref-28325163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; hospitalized patients receiving high doses may experience CDAD within days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31187275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31187275'])">Ref</a></span>); whereas, others develop gastroenteritis with long-term therapy in the community setting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365243','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365243','lexi-content-ref-28054368'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses of PPIs (eg, daily or more frequently than daily use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-28054368'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hospitalized patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28842261','lexi-content-ref-31187275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28842261','lexi-content-ref-31187275'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Infants and children with defective immune systems or indwelling catheters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25752807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25752807'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of proton pump inhibitors (PPIs), including pantoprazole, may increase the risk of <b>bone</b>
<b>fracture</b> in children, young adults, and older adults, including osteoporosis-related fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25986385','lexi-content-ref-30237993','lexi-content-ref-18695179','lexi-content-ref-32176276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25986385','lexi-content-ref-30237993','lexi-content-ref-18695179','lexi-content-ref-32176276'])">Ref</a></span>). However, data regarding the impact of PPIs on fractures, as well as bone mineral density (BMD), are inconclusive and some have concluded that any association with fracture may be related to other independent risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010681','lexi-content-ref-20458083','lexi-content-ref-30237993','lexi-content-ref-31060319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010681','lexi-content-ref-20458083','lexi-content-ref-30237993','lexi-content-ref-31060319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, hypergastrinemia and hypochlorhydria). Hypergastrinemia causes secondary hyperparathyroidism which can increase bone resorption and subsequent decreased bone mineral density. Hypochlorhydria results in decreased absorption of calcium, magnesium, and vitamin B<sub>12</sub>. Impaired calcium absorption may cause secondary hyperparathyroidism and decreased BMD. Decreased vitamin B<sub>12</sub> absorption may decrease osteoblastic activity leading to decreased BMD, as well as decreased collagen cross-linking leading to weakened bone structure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31060319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31060319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (≥1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24507954','lexi-content-ref-18695179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24507954','lexi-content-ref-18695179'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for fractures and/or osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010681','lexi-content-ref-20353792','lexi-content-ref-32058466','lexi-content-ref-30262672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010681','lexi-content-ref-20353792','lexi-content-ref-32058466','lexi-content-ref-30262672'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (eg, ≥1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24507954','lexi-content-ref-18695179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24507954','lexi-content-ref-18695179'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses of PPIs (eg, ≥1.5 doses per day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20353792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20353792'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fundic gland polyps</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of proton pump inhibitors (PPIs) has been associated with the development of reversible <b>gastric polyp </b>(fundic gland) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515','lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515','lexi-content-ref-32718584'])">Ref</a></span>). Most PPI users who developed fundic gland polyps were asymptomatic. Symptomatic patients may report nausea, vomiting, or abdominal pain. GI bleeding and/or anemia may occur with ulcerated polyp. Clinicians should note that <i>Helicobacter pylori </i>infection may be protective against fundic gland polyps as bacterial proteases help glandular outflow by breaking down blockages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32718584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; long-term use of PPIs is associated with an increase in the prevalence of parietal cell protrusions which cause outflow blockage of the isthmus and subsequent formation of fundic gland cysts. As therapy continues, fundic gland cysts may enlarge and develop into fundic gland polyps (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (&gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with familial adenomatous polyposis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of treatment (&gt;1 year and especially ≥5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions secondary to proton pump inhibitors (PPIs) range from <b>urticaria</b> to rare cases of <b>anaphylaxis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24267357','lexi-content-ref-29872353','lexi-content-ref-21626263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24267357','lexi-content-ref-29872353','lexi-content-ref-21626263'])">Ref</a></span>). Delayed hypersensitivity reactions include <b>maculopapular rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23134998','lexi-content-ref-28658503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23134998','lexi-content-ref-28658503'])">Ref</a></span>) as well as rare severe cutaneous adverse reactions (SCARs) such as <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29894542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29894542'])">Ref</a></span>), <b>drug reaction with eosinophilia and systemic symptoms</b>, <b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28658503','lexi-content-ref-17805350','lexi-content-ref-30051945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28658503','lexi-content-ref-17805350','lexi-content-ref-30051945'])">Ref</a></span>). IV pantoprazole has also been associated with <b>skin rash</b> and <b>pruritus</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic.</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria): IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24267357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24267357'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions (including maculopapular rash and SCARs): T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Rapid; occurs within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-24267357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-24267357'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions<i>:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Maculopapular reactions: Intermediate; generally occurs 7 to 10 days after initiation, but may occur up to 1 month following initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28658503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28658503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Other reactions (including SCARs): Varied; occurs after 7 to 14 days up to 3 months following initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-28658503','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-28658503','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of hypersensitivity reaction to PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16440530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16440530'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity has been noted with PPIs; although, cross-reactivity patterns have been variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30058396','lexi-content-ref-24267357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30058396','lexi-content-ref-24267357'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypomagnesemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of proton pump inhibitors (PPIs), including pantoprazole, has resulted in reversible <b>hypomagnesemia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28401712','lexi-content-ref-26108134','lexi-content-ref-18221401','lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28401712','lexi-content-ref-26108134','lexi-content-ref-18221401','lexi-content-ref-32718584'])">Ref</a></span>). Symptoms may be severe (eg, tetany, cardiac arrhythmias, cerebellar syndrome, seizures) and resistant to treatment with supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28401712','lexi-content-ref-18221401','lexi-content-ref-22800870','lexi-content-ref-20378675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28401712','lexi-content-ref-18221401','lexi-content-ref-22800870','lexi-content-ref-20378675'])">Ref</a></span>). May require discontinuation of PPI in addition to magnesium supplementation in ~25% of patients. Following discontinuation, magnesium normalizes after ~1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>). Hypomagnesemia may recur if PPI therapy is restarted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011','lexi-content-ref-21930865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011','lexi-content-ref-21930865'])">Ref</a></span>). Hypomagnesemia may lead to or exacerbate <b>hypocalcemia </b>in patients at risk (eg, hypoparathyroidism); may require calcium supplementation. Hypomagnesemia may also lead to <b>hypokalemia</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; the specific mechanism is unknown; however, long-term use of PPIs may be associated with changes in intestinal absorption of magnesium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011','lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011','lexi-content-ref-32718584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; hypomagnesemia occurs most often after 1 year of therapy but may occur as early as 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>). In patients with prior PPI-induced hypomagnesemia, re-initiation may result in recurrence within 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (≥3 months and especially &gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other drugs that cause hypomagnesemia (eg, loop diuretics, thiazide diuretics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who have undergone kidney transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31817776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31817776'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Interstitial nephritis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute interstitial nephritis </b>(AIN) may occur rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611','lexi-content-ref-19255077','lexi-content-ref-23960351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611','lexi-content-ref-19255077','lexi-content-ref-23960351'])">Ref</a></span>), with renal biopsy showing diffuse interstitial infiltrate and tubulitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24629073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24629073'])">Ref</a></span>). Patients generally achieve complete or partial recovery by 6 months following treatment for AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24927897','lexi-content-ref-17014549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24927897','lexi-content-ref-17014549'])">Ref</a></span>). Signs of systemic hypersensitivity (fever, rash, eosinophilia) often seen in other cases of drug-induced AIN are <b>not</b> typically observed in proton pump inhibitor (PPI)-induced AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611','lexi-content-ref-24927897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611','lexi-content-ref-24927897'])">Ref</a></span>). Clinicians should note that there appears to be <b>no</b> correlation between duration of exposure to PPI and duration or severity of acute renal failure after resolution of AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; unknown, although may be immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24629073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24629073'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; usually occurs within 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16630752','lexi-content-ref-17635502','lexi-content-ref-23109611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16630752','lexi-content-ref-17635502','lexi-content-ref-23109611'])">Ref</a></span>). Upon reexposure symptoms often present more rapidly, often within 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17635502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17635502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults; although this may be due to increased use of PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactions among PPIs in patients who developed AIN is not known</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Vitamin B12 deficiency</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of acid suppressive therapies, including pantoprazole, may result in reversible <b>vitamin B<sub>12</sub> deficiency</b>; however, data regarding the clinical significance of these changes and causality are conflicted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27890768','lexi-content-ref-29610598','lexi-content-ref-30792587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27890768','lexi-content-ref-29610598','lexi-content-ref-30792587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; acid suppressive therapies interfere with acid-activated proteolytic digestion of dietary protein-bound vitamin B<sub>12</sub> in the stomach, thereby resulting in malabsorption of vitamin B<sub>12 </sub>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010681','lexi-content-ref-24327038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010681','lexi-content-ref-24327038'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (≥2 to 3 years); the association between ≥2 years of PPI use and vitamin B<sub>12</sub> deficiency was stronger among people &lt;30 years of age and in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses of PPIs (≥1.5 pills per day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038','lexi-content-ref-9626024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038','lexi-content-ref-9626024'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for vitamin B<sub>12</sub> deficiency (eg, malnourished patients, vegan diet) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32718584','lexi-content-ref-21365243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32718584','lexi-content-ref-21365243'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F206202"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences are associated with adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (adults: 12%; children and adolescents: &gt;4%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (≤2%), thrombophlebitis (IV: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤2%), skin photosensitivity (≤2%), skin rash (children and adolescents: &gt;4%; adults: ≤2%), urticaria (children, adolescents, and adults: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum triglycerides (children, adolescents, and adults: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children and adolescents: &gt;4%), constipation (children, adolescents, and adults: ≤4%), diarrhea (children and adolescents: &gt;4%; adults: 9%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 1</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, flatulence (children and adolescents: ≤4%), nausea (children and adolescents: ≤4%), vomiting (children, adolescents, and adults: ≥4%), xerostomia (≤2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Pantoprazole: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pantoprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (H<sub>2</sub>-Receptor Antagonist or Another Protein Pump Inhibitor)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pantoprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (H<sub>2</sub>-Receptor Antagonist or Another Protein Pump Inhibitor)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delayed-release oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Gastroesophageal reflux disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,473</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">345</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">82</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delayed-release oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Gastroesophageal reflux disease, including erosive esophagitis associated with gastroesophageal reflux disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">249</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (≤2%), thrombocytopenia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (≤2%), increased liver enzymes (children, adolescents, and adults: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (children, adolescents, and adults: ≤4%), hypersensitivity reaction (children, adolescents, and adults: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (≤2%), dizziness (children, adolescents, and adults: ≤4%), vertigo (children, adolescents, and adults: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (children, adolescents, and adults: ≤4%), increased creatine phosphokinase in blood specimen (children, adolescents, and adults: ≤4%), myalgia (children, adolescents, and adults: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (children and adolescents: &gt;4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children and adolescents: &gt;4%; adults: ≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Miscellaneous: Laboratory test abnormality (false-positive for THC)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute coronary syndrome (Canpolat 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, cutaneous lupus erythematosus (subacute) (Almebayadh 2013, Correia 2001), maculopapular rash (Lin 2018), Stevens-Johnson syndrome (Lin 2018), toxic epidermal necrolysis (Lin 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia, hypokalemia, hypomagnesemia (Bhana 2017, Hoorn 2010), hyponatremia (Ferreira 2016), vitamin B<sub>12</sub> deficiency (Lam 2013)<b>, </b>weight changes</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, <i>Clostridioides difficile-</i>associated diarrhea, colitis (microscopic) (Verhaegh 2016), dysgeusia, gastric polyp (fundic gland; with chronic use [&gt;1 year]) (Jalving 2006), gastroenteritis (Howell 2010), pancreatitis (Das 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, neutropenia (Gouraud 2010), pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Yusoff 1999), hepatotoxicity (Aslan 2014, Meunier 2018, Sandig 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Fardet 2002, Faridaalaee 2018, Gupta 2018, Lai 2011), angioedema (Bose 2013), drug reaction with eosinophilia and systemic symptoms (Schmitz 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, confusion, dementia (Gomm 2016), drowsiness, fatigue, hallucination, insomnia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Nassar 2018), rhabdomyolysis (Yusoff 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Klassen 2013), renal disease (chronic; Lazarus 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (adults and pediatric patients 4 to 36 months of age) (Canani 2006, Eom 2011)</p></div>
<div class="block coi drugH1Div" id="F206217"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, urticaria) to pantoprazole, other substituted benzimidazole proton pump inhibitors, or any component of the formulation; in combination with rilpivirine-containing products.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F206199"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Carcinoma: Benign and malignant neoplasia has been observed in long-term (2 year) rodent studies; while not reported in humans, the relevance of these findings in regard to tumorigenicity in humans is not known.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Dosage adjustments are not required with hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel. Of the PPIs, pantoprazole has the lowest degree of CYP2C19 inhibition <i>in vitro</i> (Li 2004) and has been shown to have less effect on conversion of clopidogrel to its active metabolite compared to omeprazole (Angiolillo 2011). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham 2010; Levine 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Edetate sodium (EDTA): Some dosage forms may contain edetate sodium; use caution in patients who are at risk for zinc deficiency if other EDTA-containing solutions are coadministered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (≤7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> (Chey 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop pantoprazole treatment at least 14 days before CgA test; if CgA level is high, repeat test to confirm. Use same commercial laboratory for testing to prevent variable results.</p></div>
<div class="block foc drugH1Div" id="F206211"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Protonix: 40 mg (1 ea, 30 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Protonix: 40 mg (1 ea) [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">First Pantoprazole: 4 mg/mL (300 mL) [mint flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Protonix: 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg</p></div>
<div class="block geq drugH1Div" id="F206195"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F206219"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Pantoprazole Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $16.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Protonix Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $17.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Pantoprazole Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $3.36 - $85.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Protonix Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $6.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Pantoprazole Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.06 - $10.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.06 - $10.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Protonix Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $17.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $17.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867838"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pantoloc: 20 mg, 40 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tecta: 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg</p></div>
<div class="block adm drugH1Div" id="F206213"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Flush IV line before and after administration with D5W, NS, or LR. In-line filter not required.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>2-minute infusion:</i> The volume of reconstituted solution (4 mg/mL) may be administered IV over at least 2 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>15-minute infusion:</i> Infuse over ~15 minutes at a rate of ~7 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous infusion:</i> May also be administered as a continuous infusion for the prevention of rebleeding with in peptic ulcer bleed (off-label use).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Should be swallowed whole, do not split, crush, or chew. For most indications, administer 30 to 60 minutes before a meal (preferably); best if taken before breakfast (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419381']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419381'])">Ref</a></span>). If administering twice daily, first dose should be administered before breakfast and the second dose before dinner (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419381','lexi-content-ref-21126704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419381','lexi-content-ref-21126704'])">Ref</a></span>). Manufacturer’s labeling states that tablets may be administered with or without food and concomitant administration of antacids do not affect absorption.</p>
<p style="text-indent:-2em;margin-left:4em;">Delayed-release oral suspension: Should only be administered in apple juice or applesauce and taken ~30 minutes before a meal; do not chew or crush granules. Do not administer with any other liquid (eg, water) or foods.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral administration in <b>applesauce</b>: Sprinkle intact granules on 1 teaspoon of applesauce and swallow within 10 minutes of preparation.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral administration in <b>apple juice</b>: Empty intact granules into 5 mL of apple juice, stir for 5 seconds (granules will not dissolve), and swallow immediately after preparation. Rinse container once or twice with apple juice and swallow immediately.</p>
<p style="text-indent:-2em;margin-left:6em;">Nasogastric tube administration: Separate the plunger from the barrel of a 60 mL catheter tip syringe and connect to a ≥16 French nasogastric tube. Holding the syringe attached to the tubing as high as possible, empty the contents of the packet into barrel of the syringe, add 10 mL of apple juice and gently tap/shake the barrel of the syringe to help empty the syringe. Add an additional 10 mL of apple juice and gently tap/shake the barrel to help rinse. Repeat rinse at least twice with 10 mL aliquots of apple juice. No granules should remain in the syringe.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release tablet should be swallowed whole. Do not chew or crush. Oral suspension formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, for patients with refractory acid reflux, esophagitis, Barrett's esophagus, or ulcer, consider switching to an alternative proton pump inhibitor that is orally disintegrating (ie, lansoprazole Solutab) or a capsule formulation where contents of the capsule may be opened and taken with food (omeprazole, esomeprazole, lansoprazole). If there is inadequate response, consider escalation of therapy to twice a day or conversion to omeprazole/sodium bicarbonate or dexlansoprazole.</p></div>
<div class="block admp drugH1Div" id="F52613521"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Should be swallowed whole; do not chew or crush. May be taken without regard to meals; however, best if taken 30 minutes before a meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23629618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23629618'])">Ref</a></span>); may be administered with antacids.</p>
<p style="text-indent:-2em;margin-left:4em;">Delayed-release oral suspension: Should only be administered in apple juice or applesauce and administered 30 minutes before a meal; do not chew or crush granules. Do not administer in water, other liquids, or foods. Per manufacturer's labeling, do not divide the 40 mg delayed-release oral suspension packet to create a 20 mg dosage for pediatric patients who are unable to take the tablet formulation.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral administration in apple juice: Empty intact granules into 5 mL of apple juice, stir for 5 seconds (granules will not dissolve), and swallow immediately. Rinse container once or twice with apple juice and swallow immediately.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral administration in applesauce: Sprinkle intact granules on 1 teaspoonful of applesauce; swallow within 10 minutes of preparation. Sips of water should be administered to ensure granules are washed down into stomach; repeat sips as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Nasogastric tube administration: Separate the plunger from the barrel of a 60 mL catheter tip syringe and connect to a ≥16 French nasogastric tube. Holding the syringe attached to the tubing as high as possible, empty granules into barrel of syringe, add 10 mL of apple juice, and gently tap/shake the barrel of the syringe to help empty the syringe. Add an additional 10 mL of apple juice and gently tap/shake the barrel to help rinse. Repeat rinse at least twice more with 10 mL aliquots of apple juice. No granules should remain in the syringe.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral administration in syringe: In neonatal trials, fixed dosage packets of 2.5 mg pantoprazole were mixed with grape flavoring and 2.5 mL of water and administered immediately (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20306184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20306184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Flush IV line with NS, D5W, or LR before and after administration. Not for IM or SUBQ use.</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Administer over 2 minutes at a concentration of 4 mg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Using a 0.4 to 0.8 mg/mL solution, infuse over 15 minutes at a rate not to exceed 7 mL/minute.</p></div>
<div class="block uica drugH1Div" id="F14473039"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 80 mg in 100 mL (concentration: 0.8 mg/mL) of D5W or NS</p></div>
<div class="block meg drugH1Div" id="F15386979"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Protonix granules for oral suspension, delayed release tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F020987s060%2C022020s023lbl.pdf%23page%3D31&amp;token=iJBTths2GT3PONjY9Bayv3LtDRL4p8WzlP%2BprJT529a1wrLTkFeARSwJunO33gxA14aYF2mA72bZCcAVjMgiuOWhKHEeMFtbSEIY55lzNIbarHDo9JF%2B3GLCc9wCHdYB&amp;TOPIC_ID=9474" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020987s060,022020s023lbl.pdf#page=31</a></p></div>
<div class="block use drugH1Div" id="F206212"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Oral:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Gastroesophageal reflux disease, erosive or nonerosive: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment of erosive esophagitis</i>: Short-term treatment in the healing and symptomatic relief of erosive esophagitis in adults and pediatric patients ≥5 years of age.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance healing of erosive esophagitis:</i> Maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Zollinger-Ellison syndrome: </b>Long-term treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>IV:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Gastroesophageal reflux disease associated with a history of erosive esophagitis:</b> Short-term treatment of adult patients with gastroesophageal reflux disease and a history of erosive esophagitis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Zollinger-Ellison syndrome:</b> Treatment of adult patients with pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.</p></div>
<div class="block off-label drugH1Div" id="F25470196"><span class="drugH1">Use: Off-Label: Adult</span><p>Aspiration prophylaxis in patients undergoing anesthesia; Barrett esophagus; Dyspepsia, functional (idiopathic or non-ulcer); Eosinophilic esophagitis; Helicobacter pylori eradication; Nonsteroidal anti-inflammatory drug (including aspirin)–induced ulcers, primary prevention; Peptic ulcer disease, maintenance therapy/secondary prevention; Peptic ulcer disease, treatment of complicated ulcers; Peptic ulcer disease, treatment of uncomplicated ulcers; Stress ulcer prophylaxis in select critically ill patients; Upper GI bleed, acute (unknown etiology or peptic ulcer hemorrhage)</p></div>
<div class="block mst drugH1Div" id="F206294"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pantoprazole may be confused with ARIPiprazole</p>
<p style="text-indent:-2em;margin-left:4em;">Protonix may be confused with Lotronex, Lovenox, protamine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vials containing Protonix IV for injection are not recommended for use with spiked IV system adaptors. Nurses and pharmacists have reported breakage of the glass vials during attempts to connect spiked IV system adaptors, which may potentially result in injury to healthcare professionals.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Pantoprazole is identified in the Beers Criteria as a potentially inappropriate medications to be avoided (as scheduled use for &gt;8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection, pneumonia, GI malignancies, and bone loss/fractures unless given for high-risk patients (eg, oral corticosteroid, or chronic nonsteroidal anti-inflammatory drug use), patients with erosive esophagitis, Barrett esophagitis, or a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H<sub>2</sub> blockers) (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Protonix [US] may be confused with Pretanix brand name for indapamide [Hungary]</p>
<p style="text-indent:-2em;margin-left:4em;">Protonix: Brand name for pantoprazole [US] but also the brand name for omeprazole [Philippines]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F206277"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F206204"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Acalabrutinib. This interaction is only applicable to acalabrutinib capsules. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Atazanavir.  Management: Avoid use in treatment-experienced patients. In treatment-naive patients, administer boosted atazanavir 12 hours after the PPI and the PPI dose should not exceed the equivalent of 20 mg omeprazole. Monitor for reduced atazanavir efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with inhibitors of the proton pump (PPIs and PCABs).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors and potassium-competitive acid blockers, such as short-acting antacids or histamine-2 receptor antagonists. Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Pantoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel. Other acid-lowering therapies do not appear to share this interaction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacomitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dacomitinib.  Management: Avoid concurrent use of dacomitinib with PPIs and PCABs. Antacids may be used. Histamine H2-receptor antagonists (HR2A) may be used if dacomitinib is given at least 6 hours before or 10 hours after the H2RA.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of PPIs or PCABs if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with PPIs or PCABs should be avoided in patients treated with delavirdine. The clinical significance of short-term PPI or PCAB therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextroamphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the bioavailability of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Enoxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Gefitinib.  Management: Avoid use of inhibitors of the proton pump (PPIs or PCABs) with gefitinib when possible. If required, administer gefitinib 12 hours after the PPI/PCAB or 12 hours before the next dose of the PPI/PCAB. Closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Infigratinib. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Itraconazole. This specifically applies to the super bioavailable itraconazole products (eg, Tolsura brand). Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Itraconazole. This specifically applies to the non-super bioavailable itraconazole products (eg, Sporanox brand and its generics).  Management: Exposure to Tolsura brand itraconazole may be increased by PPIs or PCABs ; consider itraconazole dose reduction. Exposure to Sporanox brand itraconazole may be decreased. Give Sporanox brand itraconazole at least 2 hrs before or 2 hrs after PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).  Management: Administer ketoconazole with an acidic beverage, such as non-diet cola, to increase gastric acidity and improve absorption if concomitant use with proton pump inhibitors or potassium-competitive acid blockers is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Ledipasvir.  Management: PPI  or PCAB doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Use of ledipasvir with higher doses or with food, or 2 hours after a these agents, may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Levoketoconazole. Levoketoconazole may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Methotrexate.  Management: Consider temporarily interrupting PPI or PCAB therapy in patients receiving high-dose methotrexate. If coadministered, monitor for increased methotrexate toxicity (eg, mucositis, myalgias) and/or delayed methotrexate elimination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nelfinavir.  Management: Due to potentially significant reductions in nelfinavir exposure, avoid concurrent use of nelfinavir with a PPI or PCAB when possible. If unavoidable, consider PPI or PCAB use for a short duration (less than 30 days) and closely monitor viral load.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nilotinib.  Management: Avoid this combination. Histamine H2 receptor antagonists (H2RAs) given 10 hours before or 2 hours after nilotinib, or antacids given 2 hours before or 2 hours after nilotinib are acceptable alternatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Palbociclib. Specifically, this has been reported with the use of palbociclib capsules. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Palbociclib. Specifically, this may occur with the use of palbociclib capsules, and to the greatest extent when taken without food.  Management: Carefully evaluate potential risks and benefits of coadministration of palbociclib capsules and proton pump inhibitors or potassium-competitive acid blockers due to the risk of reduced palbociclib efficacy. Palbociclib capsules should be taken with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Pexidartinib.  Management: Avoid this combination. If acid-reduction is needed, consider administering an antacid 2 hours before or after pexidartinib, or administer pexidartinib 2 hours before or 10 hours after an H2 receptor antagonist.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Posaconazole.  Management: Avoid coadministration of PPIs or PCABs and posaconazole oral suspension. Posaconazole delayed-release tablets do not appear to be sensitive to this interaction and do not required dose adjustment if coadministered with PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risedronate: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Risedronate. Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.  Management: Coadministration of PPIs or PCABs with delayed-release risedronate formulations is not recommended. Limit PPI/PCAB dose and duration during coadministration with risedronate as possible. Patients over age 70 are at higher risk of adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of PPIs or PCABs and secretin, and discontinue PPI or PCAB several weeks prior to secretin administration, with the duration of separation determined by the specific acid suppressant. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and PPIs or PCABs should be avoided. If coadministration cannot be avoided, selpercatinib and PPIs or PCABs should be administered simultaneously with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Sestamibi: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Sestamibi.  Management: Consider holding/stopping proton pump inhibitor therapy for at least 3 days prior to the use technetium Tc 99m sestamibi in cardiac imaging procedures.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tetrofosmin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Tetrofosmin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: Inhibitors of the Proton Pump (PPIs and PCABs) may enhance the adverse/toxic effect of Thiazolidinediones. Specifically, the risk of osteoporosis or fracture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Velpatasvir.  Management: Sofosbuvir/velpatasvir should be administered with food and taken 4 hours before omeprazole 20 mg. Sofosbuvir/velpatasvir/voxilaprevir can be administered with omeprazole 20 mg. Use with other PPIs or PCABs has not been studied.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Voriconazole.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F24794079"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam, 2013).</p></div>
<div class="block pri drugH1Div" id="F206220"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following use of proton pump inhibitors (PPIs) during pregnancy are available (Choi 2023; Hussain 2022; Peron 2023). An increased risk of major congenital malformations has not been observed in available studies.</p>
<p style="text-indent:0em;margin-top:2em;">Recommendations for the treatment of gastroesophageal reflux disease in pregnant patients are available. When initiating treatment during pregnancy, a step-up approach, starting with diet and lifestyle modifications, is recommended. PPIs are considered acceptable for use during pregnancy when other medications are not effective (Ali 2022; Dunbar 2022; Thélin 2020).</p></div>
<div class="block brc drugH1Div" id="F206221"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Pantoprazole is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of pantoprazole in breast milk are available following administration of a single 40 mg dose to one lactating patient, 10 months postpartum. Breast milk was sampled prior to and at intervals for 24 hours after the dose. Pantoprazole was measurable in breast milk only at 2 hours (0.036 mcg/mL) and 4 hours (0.024 mcg/mL) after the maternal dose. Pantoprazole was undetectable in breast milk by 5 hours post administration. Using a milk concentration of 0.036 mcg/mL, the estimated daily infant dose via breast milk was calculated by the authors of the study to be 7.3 mcg, providing a relative infant dose (RID) of 0.14% compared to the weight-adjusted maternal dose of 40 mg. The estimated infant dose was calculated by assuming 200 mL of breast milk would be ingested around the time of the peak breast milk concentration. No adverse events were reported in the mother or infant for the 2 weeks following administration (Plante 2004). In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Data are also available following administration of pantoprazole 40 mg once daily for 7 days to 12 lactating patients who stopped breastfeeding. Breast milk was sampled at intervals over 12 hours on days 1 and 7. The mean concentrations of pantoprazole in breast milk were 0.061 mcg/mL (0.0327 to 0.141 mcg/mL) on day 1 and 0.152 mcg/mL (0.0325 to 0.7625 mcg/mL) on day 7 (Bor 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">The acidic content of a breastfed infant's stomach may potentially inactivate any pantoprazole ingested via breast milk (Plante 2004). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F206222"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;margin-left:0em;display:inline">IV: Due to EDTA in preparation, zinc supplementation may be needed in patients prone to zinc deficiency.</p></div>
<div class="block mop drugH1Div" id="F206209"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Bone loss and fractures (especially in patients on high-dose or long-term therapy [≥1 year]), <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (CDAD), magnesium (baseline and periodically thereafter; especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia), calcium (baseline and periodically in patients at risk (eg, hypoparathyroidism), and serum gastrin levels; signs or symptoms of cutaneous lupus erythematosus or systemic lupus erythematosus.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersecretory disorders: Acid output measurements, target level &lt;10 mEq/hour (&lt;5 mEq/hour if prior gastric acid-reducing surgery).</p></div>
<div class="block pha drugH1Div" id="F206198"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Proton pump inhibitor, suppresses gastric acid secretion by inhibiting the parietal cell H<sup>+</sup>/K<sup>+</sup> ATP pump</p></div>
<div class="block phk drugH1Div" id="F206216"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Acid secretion: Oral: 2.5 hours; IV: 15 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Maximum effect: IV: 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid, well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral, IV: 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents (Kearns 2008): IV (2 to 16 years of age): 0.22 ± 0.14 L/kg; Oral (5 to 16 years of age): 0.24 ± 0.09 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 11 to 23.6 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98%, primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic; CYP2C19 (demethylation), CYP3A4; no evidence that metabolites have pharmacologic activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~77%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (PMA: 37 to 44 weeks): ~3 hours (Ward 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents (Kearns 2008): IV (2 to 16 years of age): 1.22 ± 0.68 hours; Oral (5 to 16 years of age): 1.27 ± 1.29 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1 hour; increased to 3.5 to 10 hours with CYP2C19 deficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents (Kearns 2008): IV (2 to 16 years of age): 0.34 ± 0.12 hours; Oral (5 to 16 years of age): 2.54 ± 0.72 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oral: 2.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (71% as metabolites); feces (18%); pantoprazole clearance increased with weight and age (Pettersen 2009).</p></div>
<div class="block phksp drugH1Div" id="F51192050"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Increase in serum elimination half-life to 7 to 9 hours; AUC increases by 5- to 7-fold.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Pediatric patients who have the poor metabolizer genotype of CYP2C19 (CYP2C19 *2/*2) exhibited greater than a 6-fold increase in AUC compared with pediatric extensive (CYP2C19 *1/*1) and intermediate (CYP2C19 *1/*x) metabolizers. Poor metabolizers exhibited approximately 10-fold lower apparent oral clearance compared with extensive metabolizers.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Moderate increase in AUC (43%) and C<sub>max</sub> (26%) after oral administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: A modest increase in AUC and C<sub>max</sub> in women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F206223"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Gastropan | Genpol | Nupenta | Pan | Panto denk | Pantocid | Pantoloc | Pantonix | Pantor | Pantozol | Pepsolan | Proton | Razon | Topraz | Ulcipan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Actual 24 | Actual Panto 24 | Anetrum | Aziatop control | Buxifol | Faboacid Panto | Fada Pantoprazol | Gastromax | Iboprot | Ibp Panto | Pangest | Pantaltius | Pantocas | Pantomed | Pantometyl | Pantop | Pantoprazol denver farma | Pantoprazol HLB | Pantoprazol teva | Pantosepto | Pantus | Pantusec | Peptazol | Sipar | Supracam | Tecta | Uldoral | Ulserch | Zurcal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Azidex | Gastrozol | Panprabene | Pantip | Pantoloc | Pantoprazol | Pantoprazol A-Med | Pantoprazol accord | Pantoprazol actavis | Pantoprazol Alternova | Pantoprazol aptapharma | Pantoprazol Arcana | Pantoprazol Bluefish | Pantoprazol G.L. | Pantoprazol Genericon | Pantoprazol germania | Pantoprazol hikma | Pantoprazol Merck | Pantoprazol mylan | Pantoprazol nycomed | Pantoprazol Pluspharma | Pantoprazol ranbaxy | Pantoprazol ratiopharm gmbh | Pantoprazol sandoz | Pantoprazol stada | Pantozol control | Prazopant | Refluxopan | Zurcal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amcal pantoprazole heartburn relief | Apo pantoprazole | Apo pantoprazole heartburn relief | Chemmart Pantoprazole | Cm Pantoprazole | Gastenz | Heartburn Relief | Noumed pantoprazole | Ozpan | Panthron | Panto | Pantoloc | Pantoprazole actavis | Pantoprazole aft | Pantoprazole an | Pantoprazole apotex | Pantoprazole Ga | Pantoprazole Generic Health | Pantoprazole Heartburn Relief | Pantoprazole maxrx | Pantoprazole mylan | Pantoprazole Pharmacor | Pantoprazole PS | Pantoprazole sandoz | Pantoprazole sun | Pantoprazole sxp | Pharmacy care pantoprazole heartburn relief | Salpraz | Salpraz heartburn relief | Somac | Somac Heartburn Relief | Sozol | Stada pantoprazole | Suvacid Heartburn Relief | Terry White Chemist Pantoprazole | Terry white chemists pantoprazole | Topra | Torzole</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Europan | Exopan | Labpan | Neopanta | Otonix | P | P lock | Pagerd | Pamel | Panloc | Panotem | Panprazo | Panprin | Panpro | Pansec | Pansos | Pantac | Pantex | Pantid | Pantium | Panto | Pantobex | Pantochem | Pantocure | Pantodac | Pantogen | Pantogut | Pantolok | Pantomax | Panton ax | Pantonix | Pantopra | Pantover | Pantozol | Pantrol | Panzer | Pazole | Pelican | Pentosa | Pramax | Pregel | Propenta | Protium | Protocid | Proton-p | Protonil | Protopa | Topra | Tropaz | Trupan | Zopan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Brandocare | Doc Pantoprazol | Ippracid | Maalox Control | Pantogastrix | Pantomed | Pantomylan | Pantonyco | Pantopraphar | Pantoprazol ab | Pantoprazol actavis | Pantoprazol Apotex | Pantoprazol hikma | Pantoprazol krka | Pantoprazol ranbaxy | Pantoprazol sandoz | Pantoprazol teva | Pantoprazole EG | Pantoprazole mylan | Pantoprazole Nycomed | Pantoprazole ratiopharm | Pantoprazole teva | Pantozol | Refluxine | Yoevid | Zurcale</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Alcer | Galocid | Panto denk | Pantonex dr | Troypanto | Upracid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Acidwell | Controloc | Controloc Control | Helix | Noacid | Nolpaza | Nolpaza control | Panrazol | Pantoprazol aurobindo | Pantoprazol krka | Pantoprazole | Pantoprazole Zentiva | Pantul | Prazolid | Prazolpan | Pulcet</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Adipept | Combulcer | Divena | Gastropan | Gazia | Inilok | Noprop | Pantasun | Pantocal | Pantomix | Pantonax | Pantopaz | Pantoprazol | Pantoprazol sodico | Pantoprazol sodico sesqui hidratado | Pantoprazol sodico sesquihidratado | Pantozol | Pantrat | Peptovit | Prazy | Protton | Ptzol | Pyloprazol | Restitue | Tecta | Ziprol | Zurcal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Acido x | Amavita pantoprazol | Contraflux | Coop vitality pantoprazol | Gastropant Mepha | Gastrowell | Panprax | Pantofelan | Pantoprazol actavis | Pantoprazol actavis medis | Pantoprazol antacid sandoz | Pantoprazol Axapharm | Pantoprazol Helvepharm | Pantoprazol Mepha | Pantoprazol nobel | Pantoprazol nycomed | Pantoprazol orion | Pantoprazol sandoz | Pantoprazol Spirig | Pantoprazol spirig hc | Pantoprazol streuli | Pantoprazol teva | Pantoprazol viatris | Pantoprazol zentiva | Pantozol | Pantozol control | Zurcal</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Alcer | Cielpraz | Pan | Panto denk | Pantonex dr | Pantop | Pantoprazole | Sharazole | Troypanto</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Pantocal | Ulcemex | Zoltum | Zurcal</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A mo le | Firest | Kai ji | Mi ka su | Nuo sen | Pan li su | Pan mei lu | Pan shu tai ke | Pantoloc | Pantoprazole | Pantoprazole sodium | Tai mei ni ke | Wei di | Wei ke an | Xi luo shi | Zuo di</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acilibre | Adlercid | Cerazol | Gamo | Panto denk | Pantocal | Pantocid | Pantodex dr | Pantoprax | Pantoprazol | Panum | Segregam | Supacid | Tecta | Ugarpan | Zolpant | Zurcal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Panto | Controloc | Gastrolan | Gastronorm | Nolpaza | Panogastin | Pantoloc control | Pantomyl | Pantonovo | Pantoprazol +pharma | Pantoprazol accord | Pantoprazol actavis | Pantoprazol Aurovitas | Pantoprazol krka | Pantoprazol mylan | Pantoprazol olikla | Pantoprazol Pliva | Pantoprazol Tecnimede | Pantoprazole Zentiva | Pantul | Unrazol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Eupantol | Gastrozol | Genepan | Pantau Basics | Panto aristo | Pantobem | Pantogamma | Pantohennig | Pantoloc | Pantopra Q | Pantoprazol | Pantoprazol 1A Pharma | Pantoprazol Aaa | Pantoprazol abz protect | Pantoprazol Acis | Pantoprazol actavis | Pantoprazol Adgc | Pantoprazol AL | Pantoprazol ametas | Pantoprazol Aristo | Pantoprazol Atid | Pantoprazol aurobindo | Pantoprazol axicur | Pantoprazol axunio | Pantoprazol Beta | Pantoprazol Billix | Pantoprazol Biomo | Pantoprazol carino | Pantoprazol CT | Pantoprazol denk | Pantoprazol dexcel | Pantoprazol Dura | Pantoprazol Elac | Pantoprazol eris | Pantoprazol fair-med | Pantoprazol Gamma | Pantoprazol Hennig | Pantoprazol Heumann | Pantoprazol HEUNET | Pantoprazol Hexal | Pantoprazol juta | Pantoprazol Krewel | Pantoprazol Ksk | Pantoprazol macleods | Pantoprazol micro | Pantoprazol noridem | Pantoprazol Nyc | Pantoprazol orifarm | Pantoprazol Pensa | Pantoprazol puren | Pantoprazol Ratioparm | Pantoprazol ratiopharm | Pantoprazol stada | Pantoprazol sun | Pantoprazol tad | Pantoprazol tillomed | Pantoprazol Winthrop | Pantoprazole amneal | Pantoprazole Fair Med | Pantoprazole ratiopharm | Pantoprem | Pantorc | Pantozal | Pantozol | Pantozol control | Protium | Rifun | Sodac | Zurcal S</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Pantecta | Pantium | Pantoprazol | Pantoprazol Normon | Pleniva | Secrepan | Tecta | Zoltum</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acilibre | Branzol | Pantocal | Pantoprazol | Pantozol | Tecta | Zoltum | Zurcal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Anxel | Controloc Control | Ipraalox | Nolpaza | Ozzion | Pantoprazol ratiopharm | Pantoprazole Mepha | Panzilan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Antopral | Controloc | Delpanto | Futapan | Pantazol | Pantoloc | Pantomerican | Pantopi | Pantoprazole | Peptoloc | Perloc | Protofix | Stringazole | Zurcal</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alapanzol | Anagastra | Citrel | Nolpaza | Normogastrol | Panproton | Pantecta | Pantoloc control | Pantoprazol accord | Pantoprazol actavis | Pantoprazol almus | Pantoprazol Alter | Pantoprazol Apotex | Pantoprazol Aristo | Pantoprazol Aurovitas | Pantoprazol Bexal | Pantoprazol Bluefish | Pantoprazol Cinfa | Pantoprazol Codramol | Pantoprazol Combino Pharm | Pantoprazol Combix | Pantoprazol Davur | Pantoprazol Edigen | Pantoprazol G.E.S | Pantoprazol Hubber | Pantoprazol ips | Pantoprazol Kern Pharma | Pantoprazol Korhispana | Pantoprazol krka | Pantoprazol mabo | Pantoprazol macleods | Pantoprazol Mede | Pantoprazol mylan | Pantoprazol Normon | Pantoprazol Onedose | Pantoprazol pensavital | Pantoprazol pharma combix | Pantoprazol Pharmagenus | Pantoprazol Qualigen | Pantoprazol ranbaxy | Pantoprazol ratiopharm | Pantoprazol Recordati | Pantoprazol Rimafar | Pantoprazol Sala | Pantoprazol sandoz | Pantoprazol stada | Pantoprazol sun | Pantoprazol Tarbis | Pantoprazol Tecnigen | Pantoprazol teva | Pantoprazol Tevagen | Pantoprazol Vegal | Pantoprazol Winthrop | Ulcotenal</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Dosanlok | Pandev | Panopaz | Pansos | Pantaz | Panto denk | Pantoprazol mabo | Pantoprazole | Pantoprazole sodium | Pantoprime | Protocid | Reprat | Toprazole | Ultop | Utop</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Giasemin | Pantoloc control | Pantopratsoli Sun | Pantoprazol accord | Pantoprazol actavis | Pantoprazol krka | Pantoprazol mylan | Pantoprazol orifarm | Pantoprazol orion | Pantoprazol Pensa | Pantoprazol ranbaxy | Pantoprazol ratiopharm | Pantoprazol sandoz | Pantoprazol stada | Pantoprazol sun | Pantoprazole bluefish | Pantoprazole teva | Panzor | Somac | Somac Control</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Eupantol | Inipepsia | Inipomp | Ipraalox | Pancristole | Pantoloc control | Pantomed | Pantoprazole | Pantoprazole accord | Pantoprazole actavis | Pantoprazole Almus | Pantoprazole alter | Pantoprazole arrow | Pantoprazole biogaran | Pantoprazole bouchara recordati | Pantoprazole cristers | Pantoprazole EG | Pantoprazole Evolupharm | Pantoprazole hikma | Pantoprazole krka | Pantoprazole mylan pharma | Pantoprazole phr lab | Pantoprazole qualimed generiques | Pantoprazole Ranbaxy | Pantoprazole ratiopharm | Pantoprazole RPG | Pantoprazole sandoz | Pantoprazole sun | Pantoprazole teva | Pantoprazole winthrop | Pantoprazole Zentiva | Pantoprazole zydus | Pantozol control | Prazopant</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Pantoloc control | Pantoprazole | Protium</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Controloc | Gastroprozal | Noxadif | Ozepran | Pantarol | Pantium | Pantoprazole/Generics | Pantoprazole/mylan generics | Pantoprazole/tad | Pantoprol medichrom | Pantozol | Portorin | Praz up | Pronzek | Roxitrol | Ulceron | Zurcazol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo pantoprazole | Panrazol | Pantoloc | Pantoloc control | Pantoprazol farmoz | Pantoprazole | Pantoprazole normon | Pantoprazole sandoz | Pantoprazole teva | Pantostad | Peptazole | Zhikui | Zolcer</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Acipan | Apazol | Apazol a | Contragast | Controloc | Controloc Control | Nolpaza | Pantoprazol Alkaloid | Pantoprazol Genera | Pantoprazol PharmaS | Peptix | Zipantola | Zoprax</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Acida | Acidwell | Controloc | Controloc Control | Controloc magna | Gaxtron forte | Gaxtron start | Gerprazol | Noacid | Nolpaza | Nolpaza control | Pafenon | Panogastin | Panrazol | Panrazole | Pantacid | Pantacid Flux | Pantoloc control | Pantoprazol 1A Pharma | Pantoprazol accord | Pantoprazol aptapharma | Pantoprazol krka | Pantoprazol sandoz | Pantoprazol zentiva | Pantoprazole teva | Pazolexa | Ulprix | Zeladrol | Zimpax</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Caprol | Ciprazol | Ottozol | Pandecta | Panloc | Panso | Panto Gas | Pantocapri | Pantocer | Pantomex | Pantoprazole | Pantotis | Pantoz | Pantozol | Panvell | Panzol | Pepzol | Pranza | Prazopant | Pumpisel | Topazol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Gastrolief | Nolpacid | Nolpaza | Pantium | Pantoflux | Pantoloc control | Pantoprazole | PANTOPRAZOLE Bluefish | Pantoprazole bluefish | Pantoprazole teva | Pantup | Pantup Relief | Protium | Protizole | Somac Control | Zolepant</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Controloc</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">3a pan | Aciban | Acigrip p | Acipent | Aldepraz | Anleo | Arloc | Assuag | Atcid | Atopan | Auxitop | Avopan | Bipaz | Cadipanto | Cnpraz | Cocid | Controsec | Dalgut | Dipent 40 | Doctor pan | Donazol | Dragazole | Drupen | Duopep | Dupan | Dupent | Ec pan | Effipan | Elesec | Eracid | Forpan | Fritopan | Fupan | G pan | Galocid | Gerdopan | Geripan | Glanpan | Gopan | Hiperpan | Ibipanto | Ivtopraz | Jopan | Juspanta | Kairos | Kelpan | Kontrol | Leetop | Lupipan | Manez | Maxpan | Megazole 40 | Merizol | Micropan | Monpan | Mopant | Mpz | Myprazol | Nashpro | Newpan | Normocid | Nostorm | Nupan | Nupenta | Oakpan | Olgerd | Oropraz | P od | P pan | P Ppi | P praz | P Zol | P zole 40 | Pagero | Palio | Pan | Pan gal | Panasta | Panatoz | Panbloc | Pancare | Pancept | Panci | Pancicare | Pancure | Pandostal | Pandroid | Paneu | Panfast | Panfirst | Pangard | Panido | Panisa | Pankai | Panloc | Panlord | Pannav | Pano | Panoc | Panonex | Panopaz | Panotroy | Panplus | Panpot | Panprozole | Panrole | Panronix | Pansa | Pansalve | Panseal | Pansec | Panserv | Panset | Pansped | Panspeed | Pansure | Pantab | Pantabol | Pantachek | Pantacip | Pantadal | Pantadoc | Pantaford | Pantagard | Pantagon | Pantak | Pantakan | Pantakind | Pantal | Pantana | Pantapil | Pantaril | Pantaset | Pantastic | Pantax | Pantaz | Pantazol | Pantazole | Pantec | Panten | Panter | Pantica | Pantin | Pantium | Panto | Pantobis | Pantobull | Pantocalm | Pantocar | Pantocid | Pantocise | Pantocom | Pantodac | Pantodim | Pantofer | Pantofit | Pantofix | Pantogrip | Pantoka | Pantokool | Pantol | Pantolex | Pantolup | Pantom | Pantomax | Pantomed | Pantonec | Pantop | Pantopal | Pantopep | Pantophyll | Pantopol | Pantorest | Pantorica | Pantosec | Pantosig | Pantospect | Pantosun | Pantotab | Pantotaj | Pantotec | Pantova | Pantovel | Pantox | Pantoz | Pantoza | Pantoze | Pantozec | Pantozee | Pantozid | Pantozle | Pantozole | Pantru | Pantum | Panum | Panveda | Panvista | Panvoz | Panzac | Panzec | Panzo | Panzol | Panzole | Payoz | Pazes | Pazole | Pcut | Pe od | Pent od | Pentab | Pentagon | Pentalink | Pentaloc | Pentamax | Pentastar | Pentate | Pentax | Pentazole | Pentona | Pentopen | Pentosis | Pentowok | Pentra | Pentra iv | Penzolin | Penzotas | Pepcare | Pepcinova | Pepsica | Peptac | Peptazol | Pepticool | Peptilcer | Perfekt | Petiol | Pezole | Pezorpol | Pip q | Pleez | Pleze | Pnpl | Pnx | Pnz | Pnz fast | Pole | Pop | Ppbest | Ppi | Pptroy | Praize | Prat | Pratozole | Prazo | Prazotel | Praztac | Proloc | Prompt | Propanz | Proplus | Protocent | Protochek | Protopan | Pulsar | Pz 4 | Radipan | Ranpan | Rbp p | Realpan | Rinda | Royalen | Steadpan | Sv panto | Syntac | Tazol | Themipan | Tolin | Top | Topp | Toppen | Topraz | Toprazol | Topsrin | Ulkus | Ulpan | Ulrid | Ultop | Ulzar | Unopan | Uxl 40 | Vetopep | Vezole | Vrpz | Worpan | Xylopan | Zanpan | Zapoxin | Zaprol | Zepoxin | Zesofa | Zipant | Zolex | Zolpanz | Zoom | Zosecta | Zovanta</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Anafen | Appryo | Buscopan Reflusso | Dosanloc | Eugastrol reflusso | Gastroloc | Inipant | Inizol | Maalox reflusso | Nolpaza | Pancleus | Pantecta | Pantofir | Pantoloc control | Pantopan | Pantoprazolo | Pantoprazolo accord | Pantoprazolo Actavis | Pantoprazolo Age | Pantoprazolo Almus | Pantoprazolo Alter | Pantoprazolo aurobindo | Pantoprazolo bluefish | Pantoprazolo Doc | Pantoprazolo Dr Red | Pantoprazolo EG | Pantoprazolo fidia | Pantoprazolo Germed Pharma | Pantoprazolo hikma | Pantoprazolo krka | Pantoprazolo Macleods | Pantoprazolo Mylan | Pantoprazolo pensa | Pantoprazolo Ranbaxy | Pantoprazolo San | Pantoprazolo Sandoz | Pantoprazolo sun | Pantoprazolo teva | Pantoprazolo Winthrop | Pantorc | Pantorex | Peptazol | Pireflux | Prinzol | Somac Control | Xoolam reflusso | Zolemer | Zolium</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Controloc | Pantodar | Pantoloc | Pantomax | Pantoprazol sandoz | Pantover | Proton | Razon | Toprazole</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Pantonip</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Antopraz | Luganor | Pan | Pandev | Panfred | Panopaz | Pansalve | Pansec dr | Pantakind | Pantar | Pantaz | Pantin | Panto denk | Pantocid | Pantoloc | Pantonex dr | Pantor | Pantosec | Pantotab | Pantro | Pasopan | Pentofid | Reprat | Tapacid | Topraz | Trupan | Ultop | Zolpanz</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dongkoo pantoprazole | Extreme | Glopantopra | Hutozol | Panpiroc | Panpirox | Panprazol | Pantazol | Panteon | Panterrol | Pantezol | Panto k | Pantocid | Pantolaim | Pantoline | Pantoloc | Pantomed | Pantopra | Pantora | Pantostac | Pantowon | Peptazol | Peptazole | Tecta | Toprazole</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Pantera | Pantomax | Pantoprazol | Pantover | Pantozol | Proton | Toprazole</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Gastropan | Inipomp | Luganor | Pandev | Pantazole | Panthron | Pantodar | Pantoloc | Pantomax | Pantonix | Pantover | Pantozol | Penta | Razon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Anxel | Controloc | Controloc Control | Ipraalox | Nolpaza | Ozzion | Pantoprazol | Pantoprazol aurobindo | Pantoprazol bijon | Pantoprazol ratiopharm | Pantoprazole actavis | Pantoprazole ingen pharma | Pantoprazole krka | Pantoprazole Mepha | Pantoprazole torrent | Pantul | Panzilan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Brandocare | Ipraalox | Maalox Control | Pantomed | Pantoprazol Hexal | Pantoprazol ratiopharm | Pantoprazol sandoz | Pantoprazole EG | Pantozol | Refluxine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Anxel | Controloc | Controloc Control | Ipraalox | Nolpaza | Nolpaza control | Ozzion | Panogastin | Pantobax | Pantoprazole actavis | Pantoprazole Mepha | Pantoprazole unifarma | Pantul | Panzilan | Ulprix</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Eupantol | Inipomp | Pantoprazole gt</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Atzian | Ciproton | Eccer | Efectreflu | Gamo | Heliprock | Kuppam | Maakprazun | Nogaslan | Panmicid | Pantoprazol | Pantozol | Peucetol | Popram | Prazolan | Protocord | Regad | Regasef | Supacid | Tecta | Unigastrozol | Zolex | Zolpeptid | Zolpra | Zoltum</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Conpanzole | Controloc | Nolpaza | Pansec | Pantaz | Pantium | Pantobex | Pantocid | Pantomac | Pantoprazol sandoz | Pantoprazole | Pantoprazole sandoz | Pantor | Pantosec | Panzole | Peptazol | Stripole | Vaxcel pantoprazole | Vencid | Zolpra GR</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Contix | Panto denk | Pantobest | Pantomed | Pantonex dr | Pantoprazole | Pazom | Ulcostop | Vpl pantoprazole</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ipraalox | Maagzuurtabletten HTP Pantoprazol | Maagzuurtabletten pantoprazol | Pantoprazol | Pantoprazol A | Pantoprazol accord | Pantoprazol actavis | Pantoprazol Apotex | Pantoprazol mylan | Pantoprazol nycomed | Pantoprazol Phc | Pantoprazol ratiopharm | Pantoprazol sandoz | Pantorc | Pantozol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Controloc | Pantoloc control | Pantoprazol actavis | Pantoprazol oresund pharma | Pantoprazol Pensa | Pantoprazol sandoz | Pantoprazol sun | Somac | Somac Control</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Noumed pantoprazole | Pantocid | Pantoprazole | Pantoprazole actavis | Panzop relief | Somac</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acinil p 40 | Enterocoll | Fexmor | Gaspan | Gastrolud | Gastropan | Melopral | Pan | Pansec | Pantakind | Pantium | Panto frenacid | Pantocalm | Pantocid | Pantogastrin | Pantokem | Pantomek | Pantopharm | Pantopralip | Pantopranex | Pantoprazol | Penstal | Sumipral | Tonval | Ulcerend t | Zoltum | Zurcal</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acernix | Acicare | Acrid | Amphoter | Antaxid | Axepron | Berapraz | Centrapraz | Clessol | Depanto | Durazol | Eloprix | Enpen | Esopan | Hypanto | Marozel | Nahalpraz | Ozepran | Panlox | Panpraz | Pantaz | Pantobbas | Pantocar | Pantocare | Pantokem | Pantoloc | Pantomax | Pantomerk | Pantopraz | Pantoprazole | Pantoprime | Pantopron | Pantor | Pantovex | Pantovic | Pantowell | Pantoxac | Pantozol | Pantro | Pantrozole | Panum | Panwin | Panzol | Penstal | Pentowin | Pentoza | Prasenz | Prasiloc | Pratozol | Prazobloc | Prazole | Prazole forte | Reductazid | Ritemed pantoprazole | Sitipraz | Suppi | Tamiga pan | Ulcepraz | Vexprazole | Vuepan | Zolpra</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alenprol | Apton | Awamed | Biotop | Biozole | Biskar | Camree | Cantrofast | Clessol | Controloc | Dewpan | Elspar | Esophil | Fantozole | Filzorin | Fitral | Freesia | Gastasid | Genopra | Genopra dr | Glovar | Kanprazole | Kinzole | Lexcid | Lopaze | Maxor | Neege | Neupanto | Nupenta | Operazol | Pamzim | Pancap | Pancy | Panot | Pansec | Pansi | Pantacool | Pantafaz | Pantakure | Pantaz | Pantberg | Pantecta | Pantocal | Pantogerd | Pantomed | Pantop | Pantorid | Pantosel | Pantosol | Pantowen | Pantozol | Pantroloc | Pantroz | Panzet | Panzol | Paprazole | Pazol | Pazole | Penmark | Pentazole | Pentium | Pento | Pentopal | Pentorel | Penzol | Peprant | Peptia | Perizole | Perzol | Petronex | Pnzop | Pristij | Progard | Promax | Propazet | Propenta | Protium | Protofix | Protonix | Protonol | Rakazol | Reflexol | Rubal | Sb Zol | Scipant | Shazol | Toprazol | Toprazole | Torazole | Unipro | Worx | Zentro | Zolpride | Zopent | Zopium | Zotec | Zotonix | Zovanta</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anesteloc | Anesteloc max | Contix | Contix Zrd | Contracid | Controloc | Controloc Control | Gastrostad | Gerdin | Gerdin max | Ipp | Noacid | Nolpaza | Nolpaza control | Ozzion | Pamyl | Panogastin | Panprazox | Panrazol | Pantogen | Pantopraz | Pantoprazol accord | Pantoprazol krka | Pantoprazol ratiopharm | Pantoprazol sandoz | Pantoprazol sun | Pantoprazol teva | Pantoprazol vitama | Pantoprazole | Pantoprazole arrow | Pantoprazole aurovitas | Pantoprazole genoptim | Pantoprazole Genoptim SPH | Pantoprazole mercapharm | Pantoprazole reig jofre | Pantoprazolum Farmacom | Pantorena | Pantosis max | Panzol | Prazolacid | Prazopant | Ranloc | Ranloc med | Xotepic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pantoprazole | Pantoprazole sodium | Pantoprazole sodium delayed release | Protonix</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Apton | Digespan | Kairol | Mag | Pantoc | Pantoloc control | Pantoprazol | Pantoprazol almus | Pantoprazol Altan | Pantoprazol aurobindo | Pantoprazol Aurovitas | Pantoprazol Azevedos | Pantoprazol basi | Pantoprazol Bluefish | Pantoprazol Ciclum | Pantoprazol Daquimed | Pantoprazol generis | Pantoprazol hikma | Pantoprazol Labesfal | Pantoprazol mylan | Pantoprazol nospi | Pantoprazol panrazol | Pantoprazol Pharmakern | Pantoprazol ratiopharm | Pantoprazol sandoz | Pantoprazol sidefarma | Pantoprazol teva | Pantoprazol vida | Pantoprazol wynn | Pantoprazole | Redacib | Zipantol | Zurcal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aziatop | Gastromax | Pantoprazol imedic | Pantoprazol pharmavial | Pepticus | Ulcemex</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Luganor | Pandev | Panocer | Pantactive | Pantoloc | Pantonix IV | Pantoprazole (Sandoz) | Pantor | Pantover | Pantozol | Pantozyn | Proton | Razon | Topraz | Toprazole</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Azatol | Controloc | Controloc Control | Dicarbocalm control | Gesoflux | Nolpanta | Nolpaza | Pantoprazol aurobindo | Pantoprazol rompharm | Pantoprazol sun | Pantoprazol teva | Pantoprazol torrent | Pantor | Redacib | Seltraz | Zencopan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Controloc | Krosacid | Nolpaza | Pantaz | Pantoprazole | Pantoprazole akrikhin | Pantoprazole Canon | Pantoprazole teva | Panum | Peptazol | Pijenum | Pizhenum sanovel | Puloref | Sunpraz | Ultera | Zipantola</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo pantoprazole | Panlock | Pantium | Pantol | Pantoloc | Pantomax | Pantonix | Pantover | Pantozol | Pantrox | Pepsolan | Proton | Razon | Riapanta | Toprazole</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Pantoloc | Pantoloc control | Pantoprazol 2care4 | Pantoprazol accord | Pantoprazol actavis | Pantoprazol aurobindo | Pantoprazol bijon | Pantoprazol ebb | Pantoprazol krka | Pantoprazol mylan | Pantoprazol oresund pharma | Pantoprazol orifarm | Pantoprazol orion | Pantoprazol Pensa | Pantoprazol ranbaxy | Pantoprazol ratiopharm | Pantoprazol sandoz | Pantoprazol stada | Pantoprazol sun | Pantoprazol teva | Pantoprazole bluefish | Pantoprazole teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Controloc | Duonazole | Pantoprazole normon | Pantoprazole sandoz | Panzole | Peptazol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Acipan | Acistop | Controloc | Controloc Control | Ipraalox | Nolpaza | Nolpaza control | Panrazol | Pansemyl | Pantoprazol actavis | Pantoprazol apta | Pantoprazol teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Controloc | Controloc Control | Dyspex | Gastronorm | Ipraalox | Nolpaza | Ozzion | Panogastin | Pantoloc control | Pantomyl | Pantoprazol krka | Pantoprazol mylan | Pantoprazol ratiopharm | Pantoprazol sandoz | Ulprix</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Controloc | Pantocid | Pantoprazol sandoz | Pantoprol | Pantoval | Pms-Pantoprazole | Ulced IV</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Inipomp | Pantopral | Razon</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Abpax | Arinna | Gastblok | Gastrazol L | Pandev | Panocer | Panref | Pantactive | Panthec | Panto | Pantonix | Pantozol | Pantpas | Penzol | Progas | Protaz | Protech | Protinum | Protonex | Pulcet | Stamic | Ulcezol | Ulcoreks | Ulsepan | Zolcer | Zygosis</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo pantoprazole | Controloc | Gisowed gastro res | Panho | Pantazol | Pantoloc | Pantoprazole | Pantyl | Panzolec | Panzolec lyo inj | Pozola | Wenice</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Controloc | Espa prazol | Nolpaza | Nolpaza controll | Pangastro | Panocid | Pantamac | Pantopraz | Pantoprazole | Pantoprazole euro | Pantor | Pantosandoz | Pantozol | Panum | Prazofest | Protera | Protera controll | Proxium | Topraz | Ulsepan | Ultera</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Aarpanto | Lerole | Pan | Pantaz | Pantin | Panto denk | Pantonex dr | Pantonix | Pantotab | Panum | Panzole | Pentalink | Salpraz</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bransec | Branzol | Pantocal | Pantoprazol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hitop | Inibil | Pantocalm | Pantop | Pantoprazol | Pantoprazol sodico | Pantorol | Pantospen | Panum | Pranza | Supacid | Tecta | Ulpratop | Zoltum | Zovanta</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Comenazol | Dogastrol | Enorgapan | Europanta | Mepantop | Oziapanto | Pantagi | Pantonew | Pantonova | Pantostad | Pipanzin | Qapanto | Vintolox</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco pantoprazole | Aspen Pantoprazole | Conoran | Controloc | Gastriwin | Ivacid | Mylan Pantoprazole | Pantakind | Pantocid | Pantoloc | Pantoprazole specpharm | Pantoprazole unicorn | Pantor | Pentoz | Pentoz otc | Peploc | Peptazol | Prazant | Prazgen otc | Prazoloc | Praztek | Topraflux | Topzole | Viapan</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Pantakind | Pantaz | Panto denk | Pantonex dr | Pentalink | Rypanta | Trupan | Upracid</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Topzole</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010681">
<a name="23010681"></a>Abraham NS. Proton pump inhibitors: potential adverse effects. <i>Curr Opin Gastroenterol</i>. 2012;28(6):615-620. doi:10.1097/MOG.0b013e328358d5b9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23010681/pubmed" id="23010681" target="_blank">23010681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. <i>Circulation</i>. 2010;122(24):2619-2633. doi: 10.1161/CIR.0b013e318202f701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24507954">
<a name="24507954"></a>Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. <i>Ann Epidemiol</i>. 2014;24(4):286-90. doi:10.1016/j.annepidem.2014.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24507954/pubmed" id="24507954" target="_blank">24507954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27398293">
<a name="27398293"></a>Aggarwal N. Drug-induced subacute cutaneous lupus erythematosus associated with proton pump inhibitors. <i>Drugs Real World Outcomes</i>. 2016;3(2):145-154. doi:10.1007/s40801-016-0067-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/27398293/pubmed" id="27398293" target="_blank">27398293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28459708">
<a name="28459708"></a>Alhazzani W, Guyatt G, Alshahrani M, et al; Canadian Critical Care Trials Group. Withholding pantoprazole for stress ulcer prophylaxis in critically ill patients: a pilot randomized clinical trial and meta-analysis. <i>Crit Care Med</i>. 2017;45(7):1121-1129. doi: 10.1097/CCM.0000000000002461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28459708/pubmed" id="28459708" target="_blank">28459708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35508989">
<a name="35508989"></a>Ali RAR, Hassan J, Egan LJ. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. <i>BMC Gastroenterol</i>. 2022;22(1):219. doi:10.1186/s12876-022-02287-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/35508989/pubmed" id="35508989" target="_blank">35508989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23548825">
<a name="23548825"></a>Almebayadh M, Regnier-Rosencher E, Carlotti A, et al. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors. <i>Dermatology</i>. 2013;226(2):119-23. doi:10.1159/000346694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23548825/pubmed" id="23548825" target="_blank">23548825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28045707">
<a name="28045707"></a>American Society of Anesthesiologists. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. <i>Anesthesiology</i>. 2017;126(3):376-393. doi: 10.1097/ALN.0000000000001452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28045707/pubmed" id="28045707" target="_blank">28045707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8827397">
<a name="8827397"></a>Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. <i>Clin Pharmacokinet</i>. 1996;31(1):9‐28. doi:10.2165/00003088-199631010-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/8827397/pubmed" id="8827397" target="_blank">8827397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20844485">
<a name="20844485"></a>Angiolillo DJ, Gibson CM, Cheng S, et al, “Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies,” <i>Clin Pharmacol Ther</i>, 2011, 89(1):65-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20844485/pubmed" id="20844485" target="_blank">20844485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24652021">
<a name="24652021"></a>Aslan M, Celik Y, Karadas S, Olmez S, Cifci A. Liver hepatotoxicity associated with pantoprazole: a rare case report. <i>Wien Klin Wochenschr</i>. 2014;126(11-12):390-392. doi:10.1007/s00508-014-0535-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24652021/pubmed" id="24652021" target="_blank">24652021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26790552">
<a name="26790552"></a>Babic Z, Bogdanovic Z, Dorosulic Z, et al. One year treatment of Barrett's esophagus with proton pump inhibitors (a multi-center study). <i>Acta Clin Belg</i>. 2015;70(6):408-413. doi: 10.1080/17843286.2015.1107203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26790552/pubmed" id="26790552" target="_blank">26790552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20522615">
<a name="20522615"></a>Baker R, Tsou VM, Tung J, et al. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. <i>Clin Pediatr (Phila).</i> 2010;49(9):852-865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20522615/pubmed" id="20522615" target="_blank">20522615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31634917">
<a name="31634917"></a>Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. <i>Ann Intern Med</i>. 2019;171(11):805‐822. doi:10.7326/M19-1795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/31634917/pubmed" id="31634917" target="_blank">31634917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20083829">
<a name="20083829"></a>Barkun AN, Bardou M, Kuipers EJ, et al; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. <i>Ann Intern Med</i>. 2010;152(2):101-113. doi:10.7326/0003-4819-152-2-201001190-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20083829/pubmed" id="20083829" target="_blank">20083829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27163192">
<a name="27163192"></a>Barletta JF, Bruno JJ, Buckley MS, Cook DJ. Stress ulcer prophylaxis. <i>Crit Care Med</i>. 2016;44(7):1395-1405. doi: 10.1097/CCM.0000000000001872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/27163192/pubmed" id="27163192" target="_blank">27163192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8180291">
<a name="8180291"></a>Benet LZ, Zech K. Pharmacokinetics--a relevant factor for the choice of a drug? <i>Aliment Pharmacol Ther</i>. 1994;8(suppl 1):25‐32. doi:10.1111/j.1365-2036.1994.tb00225.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/8180291/pubmed" id="8180291" target="_blank">8180291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058396">
<a name="30058396"></a>Benito-Garcia F, Chambel M, Morais-Almeida M. Anaphylaxis due to proton pump inhibitors: current understanding and important clinical considerations. <i>Expert Rev Clin Immunol</i>. 2018;14(8):653-656. doi:10.1080/1744666X.2018.1505504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30058396/pubmed" id="30058396" target="_blank">30058396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bergsland.2020">
<a name="Bergsland.2020"></a>Bergsland E. Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed September 23, 2020. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24629073">
<a name="24629073"></a>Berney-Meyer L, Hung N, Slatter T, Schollum JB, Kitching AR, Walker RJ. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury? <i>Nephrology (Carlton)</i>. 2014;19(6):359-365. doi:10.1111/nep.12226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24629073/pubmed" id="24629073" target="_blank">24629073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28401712">
<a name="28401712"></a>Bhana A, Waters MJ, Fazal MW, Kimber T. Pantoprazole-induced hypomagnesaemia causing cerebellar syndrome and seizures. <i>Intern Med J</i>. 2017;47(4):467-468. doi:10.1111/imj.13388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28401712/pubmed" id="28401712" target="_blank">28401712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21655020">
<a name="21655020"></a>Bhattacharyya T, Sarbapalli D, Pal R, et al. Evaluating ranitidine, pantoprazole and placebo on gastric pH in elective surgery. <i>Saudi J Anaesth</i>. 2011;5(1):67-72. doi:10.4103/1658-354X.76508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21655020/pubmed" id="21655020" target="_blank">21655020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10975769">
<a name="10975769"></a>Bianchi Porro G, Lazzaroni M, Imbesi V, Montrone F, Santagada T. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. <i>Dig Liver Dis</i>. 2000;32(3):201-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10975769/pubmed" id="10975769" target="_blank">10975769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bonis.1">
<a name="Bonis.1"></a>Bonis PAL, Gupta SK. Treatment of eosinophilic esophagitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bor.1">
<a name="Bor.1"></a>Bor S, Karacaoglu S, Ergun P Kipcak S, Turkyilmaz G, Karasulu E. The levels of pantoprazole in human breast milk and plasma: two compartment model. <i>Neurogastroenterol Motil</i>. 2017;29:79-80. Abstract. https://onlinelibrary.wiley.com/doi/epdf/10.1111/nmo.13180.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24267357">
<a name="24267357"></a>Bose S, Guyer A, Long A, Banerji A. Evaluation and management of hypersensitivity to proton pump inhibitors. <i>Ann Allergy Asthma Immunol</i>. 2013;111(6):452-457. doi:10.1016/j.anai.2013.08.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24267357/pubmed" id="24267357" target="_blank">24267357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34376087">
<a name="34376087"></a>Callaway K, Lakkad M, Painter JT, Dayer L, Oswalt AK. The impact of continuous infusion compared to intravenous bolus administration of pantoprazole on length of intensive care unit stay in critically ill patients. <i>J Pharm Pract.</i> 2021:8971900211036096. doi:10.1177/08971900211036096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/34376087/pubmed" id="34376087" target="_blank">34376087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16651285">
<a name="16651285"></a>Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. <i>Pediatrics.</i> 2006;117(5):e817-e820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16651285/pubmed" id="16651285" target="_blank">16651285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22192298">
<a name="22192298"></a>Canpolat U, Şahiner L, Aytemir K, Oto A. Allergic reaction to proton pump ınhibitor: pantoprazole induced Kounis syndrome. <i>Int J Cardiol</i>. 2012;159(2):e27-e28. doi:10.1016/j.ijcard.2011.11.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22192298/pubmed" id="22192298" target="_blank">22192298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28842261">
<a name="28842261"></a>Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of <i>Clostridium difficile</i> infection. <i>J Hosp Infect</i>. 2018;98(1):4-13. doi:10.1016/j.jhin.2017.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28842261/pubmed" id="28842261" target="_blank">28842261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26108134">
<a name="26108134"></a>Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. <i>Ren Fail</i>. 2015;37(7):1237-1241. doi:10.3109/0886022X.2015.1057800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26108134/pubmed" id="26108134" target="_blank">26108134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28071659">
<a name="28071659"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28071659/pubmed" id="28071659" target="_blank">28071659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD, Wong BC, et al. American College of Gastroenterology guideline on the management of <i>Helicobacter pylori</i> infection. <i>Am J Gastroent.</i> 2007;102(8):1808-1825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19686407">
<a name="19686407"></a>Choi KD, Kim N, Jang IJ, et al. Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea. <i>J Gastroenterol Hepatol</i>. 2009;24(10):1617-1624. doi:10.1111/j.1440-1746.2009.05939.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19686407/pubmed" id="19686407" target="_blank">19686407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36626173">
<a name="36626173"></a>Choi A, Noh Y, Jeong HE, et al. Association between proton pump inhibitor use during early pregnancy and risk of congenital malformations. <i>JAMA Netw Open</i>. 2023;6(1):e2250366. doi:10.1001/jamanetworkopen.2022.50366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/36626173/pubmed" id="36626173" target="_blank">36626173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23134998">
<a name="23134998"></a>Chularojanamontri L, Jiamton S, Manapajon A, et al. Cutaneous reactions to proton pump inhibitors: a case-control study. <i>J Drugs Dermatol</i>. 2012;11(10):e43-e47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23134998/pubmed" id="23134998" target="_blank">23134998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25752807">
<a name="25752807"></a>Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. <i>Br J Clin Pharmacol</i>. 2015;80(2):200-208. doi:10.1111/bcp.12619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/25752807/pubmed" id="25752807" target="_blank">25752807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16440530">
<a name="16440530"></a>Confino-Cohen R, Goldberg A. Anaphylaxis to omeprazole: diagnosis and desensitization protocol. <i>Ann Allergy Asthma Immunol</i>. 2006;96(1):33-36. doi:10.1016/S1081-1206(10)61037-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16440530/pubmed" id="16440530" target="_blank">16440530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31378636">
<a name="31378636"></a>Corley DA. Safety and complications of long-term proton pump inhibitor therapy: Getting closer to the truth. <i>Gastroenterology</i>. 2019;157(3):604-607. doi:10.1053/j.gastro.2019.07.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/31378636/pubmed" id="31378636" target="_blank">31378636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20353792">
<a name="20353792"></a>Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. <i>Gastroenterology</i>. 2010;139(1):93-101. doi:10.1053/j.gastro.2010.03.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20353792/pubmed" id="20353792" target="_blank">20353792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11488838">
<a name="11488838"></a>Correia O, Lomba Viana H, Azevedo R, Delgado L, Polónia J. Possible phototoxicity with subsequent progression to discoid lupus following pantoprazole administration. <i>Clin Exp Dermatol</i>. 2001;26(5):455-456. doi:10.1046/j.1365-2230.2001.00857.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/11488838/pubmed" id="11488838" target="_blank">11488838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7781461">
<a name="7781461"></a>Cremer M, Lambert R, Lamers CB, Delle Fave G, Maier C; European Pantoprazole Study Group. A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer: a multicenter trial. <i>Dig Dis Sci</i>. 1995;40(6):1360-1364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/7781461/pubmed" id="7781461" target="_blank">7781461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crowe.2020">
<a name="Crowe.2020"></a>Crowe SE. Treatment regimens for Helicobacter pylori. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed February 7, 2020. <a href="https://www.uptodate.com/contents/nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity?search=NSAIDS%20%28including%20aspirin%29&amp;source=search_result&amp;selectedTitle=3~150&amp;usage_type=default&amp;display_rank=3" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19761935">
<a name="19761935"></a>Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. <i>J Am Coll Cardiol</i>. 2009;54(13):1149-1153. doi: 10.1016/j.jacc.2009.05.050.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19761935/pubmed" id="19761935" target="_blank">19761935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18221401">
<a name="18221401"></a>Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. <i>Clin Endocrinol (Oxf)</i>. 2008;69(2):338-341. doi:10.1111/j.1365-2265.2008.03194.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18221401/pubmed" id="18221401" target="_blank">18221401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18176768">
<a name="18176768"></a>Dam C, Bygum A. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. <i>Acta Derm Venereol</i>. 2008;88(1):87-89. doi:10.2340/00015555-0335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18176768/pubmed" id="18176768" target="_blank">18176768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22495426">
<a name="22495426"></a>Das S, Ganguly A, Ghosh A, Mondal S, Dey JK, Saha I. Oral pantoprazole-induced acute pancreatitis in an 11-year-old child. <i>Ther Drug Monit</i>. 2012;34(3):242-244. doi:10.1097/FTD.0b013e3182526e6a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22495426/pubmed" id="22495426" target="_blank">22495426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31817776">
<a name="31817776"></a>Douwes RM, Gomes-Neto AW, Schutten JC, et al. Proton-pump inhibitors and hypomagnesaemia in kidney transplant recipients. <i>J Clin Med</i>. 2019;8(12):2162. doi:10.3390/jcm8122162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/31817776/pubmed" id="31817776" target="_blank">31817776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36194028">
<a name="36194028"></a>Dunbar K, Yadlapati R, Konda V. Heartburn, nausea, and vomiting during pregnancy. <i>Am J Gastroenterol</i>. 2022;117(10S):10-15. doi:10.14309/ajg.0000000000001958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/36194028/pubmed" id="36194028" target="_blank">36194028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29915158">
<a name="29915158"></a>Eichenwald EC; Committee on Fetus and Newborn. Diagnosis and management of gastroesophageal reflux in preterm infants [published online July 2, 2018]. <i>Pediatrics</i>. 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/29915158/pubmed" id="29915158" target="_blank">29915158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21173070">
<a name="21173070"></a>Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. <i>CMAJ</i>. 2011;183(3):310-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21173070/pubmed" id="21173070" target="_blank">21173070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22314213">
<a name="22314213"></a>Erichsen R, Mikkelsen E, Pedersen L, et al, "Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring," <i>Am J Ther</i>, 2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22314213/pubmed" id="22314213" target="_blank">22314213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27102658">
<a name="27102658"></a>Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/27102658/pubmed" id="27102658" target="_blank">27102658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22800870">
<a name="22800870"></a>Famularo G, Minisola G, Bravi MC, Colucci P, Gasbarrone L. Tetany, hypomagnesemia, and proton-pump inhibitors. <i>Am J Med</i>. 2012 Oct;125(10):e7-e8. doi:10.1016/j.amjmed.2012.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22800870/pubmed" id="22800870" target="_blank">22800870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12425583">
<a name="12425583"></a>Fardet L, Izzedine H, Ciroldi M, Tiev KP, Cabane J. Pantoprazole-induced recurrent anaphylactic shock. <i>Am J Gastroenterol</i>. 2002;97(11):2933. doi:10.1111/j.1572-0241.2002.07085.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/12425583/pubmed" id="12425583" target="_blank">12425583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30009236">
<a name="30009236"></a>Faridaalaee G, Ahmadian Heris J. Anaphylaxis as a rare side effect of pantoprazole; a case report. <i>Emerg (Tehran)</i>. 2018;6(1):e34<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30009236/pubmed" id="30009236" target="_blank">30009236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fass.2019">
<a name="Fass.2019"></a>Fass R. Approach to refractory gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed November 11, 2019. <a href="https://www.uptodate.com/contents/nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity?search=NSAIDS%20%28including%20aspirin%29&amp;source=search_result&amp;selectedTitle=3~150&amp;usage_type=default&amp;display_rank=3" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35898254">
<a name="35898254"></a>Faust AC, Schwaner L, Thomas D, Sannapanei S, Feldman M. Pre-endoscopy use of proton pump inhibitor intravenous bolus dosing in hemodynamically stable patients with suspected upper gastrointestinal bleeding: results of a pharmacist-managed hospital protocol to reduce continuous infusion pantoprazole use. <i>Hosp Pharm.</i> 2022;57(4):448-454. doi:10.1177/00185787211046854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/35898254/pubmed" id="35898254" target="_blank">35898254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30755856">
<a name="30755856"></a>Ferreira F, Mateus S, Santos AR, Moreira H, Ferreira NR. Pantoprazole-related symptomatic hyponatremia. <i>Eur J Case Rep Intern Med</i>. 2016;3(2):000341. doi:10.12890/2015_000341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30755856/pubmed" id="30755856" target="_blank">30755856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.2019">
<a name="Feldman.2019"></a>Feldman M. NSAIDs (including aspirin): secondary prevention of gastroduodenal toxicity. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed November 11, 2019a. <a href="https://www.uptodate.com/contents/nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity?search=NSAIDS%20%28including%20aspirin%29&amp;source=search_result&amp;selectedTitle=3~150&amp;usage_type=default&amp;display_rank=3" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.2019.1">
<a name="Feldman.2019.1"></a>Feldman M, Das S. NSAIDs (including aspirin): primary prevention of gastroduodenal toxicity. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity?search=NSAIDS%20%28including%20aspirin%29&amp;source=search_result&amp;selectedTitle=3~150&amp;usage_type=default&amp;display_rank=3" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2011">
<a name="FDA.2011"></a>Food and Drug Administration (FDA). FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Published March 2, 2011. Accessed September 9, 2020. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25986385">
<a name="25986385"></a>Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. <i>Osteoporos Int</i>. 2015;26(10):2501-7. doi:10.1007/s00198-015-3168-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/25986385/pubmed" id="25986385" target="_blank">25986385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16630752">
<a name="16630752"></a>Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. <i>Clin Gastroenterol Hepatol</i>. 2006;4(5):597-604. doi:10.1016/j.cgh.2005.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16630752/pubmed" id="16630752" target="_blank">16630752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26882076">
<a name="26882076"></a>Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. <i>JAMA Neurol</i>. 2016;73(4):410-416. doi:10.1001/jamaneurol.2015.4791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26882076/pubmed" id="26882076" target="_blank">26882076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20586518">
<a name="20586518"></a>Gouraud A, Vochelle V, Descotes J, Vial T. Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole. <i>Clin Drug Investig</i>. 2010;30(8):559-563. doi:10.2165/11537230-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20586518/pubmed" id="20586518" target="_blank">20586518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33567467">
<a name="33567467"></a>Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2021. <i>Endoscopy</i>. 2021;53(3):300-332. doi:10.1055/a-1369-5274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/33567467/pubmed" id="33567467" target="_blank">33567467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20458083">
<a name="20458083"></a>Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. <i>Arch Intern Med</i>. 2010;170(9):765-771. doi:10.1001/archinternmed.2010.94<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20458083/pubmed" id="20458083" target="_blank">20458083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29872353">
<a name="29872353"></a>Gupta PP, Bhandari R, Mishra DR, et al. Anaphylactic reactions due to pantoprazole: case report of two cases. <i>Int Med Case Rep J</i>. 2018;11:125-127. doi:10.2147/IMCRJ.S153099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/29872353/pubmed" id="29872353" target="_blank">29872353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32639541">
<a name="32639541"></a>Hall EL, Peravali R, Patel TS. Omeprazole-induced subacute cutaneous lupus erythematosus. <i>JAMA Dermatol</i>. 2020;156(9):1013. doi:10.1001/jamadermatol.2020.2415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/32639541/pubmed" id="32639541" target="_blank">32639541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25192903">
<a name="25192903"></a>Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. <i>Fam Pract</i>. 2014;31(6):625-630. doi:10.1093/fampra/cmu050.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/25192903/pubmed" id="25192903" target="_blank">25192903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17635502">
<a name="17635502"></a>Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. <i>Br J Clin Pharmacol</i>. 2007;64(6):819-823. doi:10.1111/j.1365-2125.2007.02927.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17635502/pubmed" id="17635502" target="_blank">17635502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21126704">
<a name="21126704"></a>Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. <i>Best Pract Res Clin Gastroenterol</i>. 2010;24(6):923-936.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21126704/pubmed" id="21126704" target="_blank">21126704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32359562">
<a name="32359562"></a>Hirano I, Chan ES, Rank MA, et al; AGA Institute Clinical Guidelines Committee; Joint Task Force on Allergy-Immunology Practice Parameters. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. <i>Gastroenterology</i>. 2020;158(6):1776-1786. doi:10.1053/j.gastro.2020.02.03<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/32359562/pubmed" id="32359562" target="_blank">32359562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holmes.2019">
<a name="Holmes.2019"></a>Holmes DR Jr, Sorajja P. Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20189276">
<a name="20189276"></a>Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. <i>Am J Kidney Dis</i>. 2010;56(1):112-116. doi:10.1053/j.ajkd.2009.11.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20189276/pubmed" id="20189276" target="_blank">20189276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20458086">
<a name="20458086"></a>Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial <i>Clostridium difficile</i> infection. <i>Arch Intern Med</i>. 2010;170(9):784-90. doi:10.1001/archinternmed.2010.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20458086/pubmed" id="20458086" target="_blank">20458086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34889253">
<a name="34889253"></a>Hsieh HH, Wu TY, Chen CH, Hour MJ. Cost-effectiveness and clinical outcomes of intermittent/continuous proton pump inhibitors infusion in high bleeding risk of ulcers: a retrospective observational cohort study. <i>Medicine (Baltimore).</i> 2021;100(49):e28064. doi:10.1097/MD.0000000000028064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/34889253/pubmed" id="34889253" target="_blank">34889253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20233195">
<a name="20233195"></a>Hsu YC, Perng CL, Yang TH, et al. A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding. <i>Br J Clin Pharmacol</i>. 2010;69(3):245-251. doi:10.1111/j.1365-2125.2009.03575.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20233195/pubmed" id="20233195" target="_blank">20233195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28072858">
<a name="28072858"></a>Hu Q, Sun TT, Hong J, Fang JY, Xiong H, Meltzer SJ. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett's Esophagus: a systematic review and meta-analysis. <i>PLoS One</i>. 2017;12(1):e0169691. doi:10.1371/journal.pone.0169691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28072858/pubmed" id="28072858" target="_blank">28072858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17635283">
<a name="17635283"></a>Hung WK, Li VK, Chung CK, et al. Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers. <i>ANZ J Surg</i>. 2007;77(8):677-681. doi:10.1111/j.1445-2197.2007.04185.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17635283/pubmed" id="17635283" target="_blank">17635283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36012913">
<a name="36012913"></a>Hussain S, Singh A, Antony B, et al. Proton pump inhibitors use and risk of preeclampsia: a meta- analysis. <i>J Clin Med</i>. 2022;11(16):4675. doi:10.3390/jcm11164675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/36012913/pubmed" id="36012913" target="_blank">36012913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28886621">
<a name="28886621"></a>Ibanez B, James S, Agewall S, et al; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting With ST-segment Elevation of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28886621/pubmed" id="28886621" target="_blank">28886621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17059515">
<a name="17059515"></a>Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. <i>Aliment Pharmacol Ther</i>. 2006;24(9):1341-1248. doi:10.1111/j.1365-2036.2006.03127.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17059515/pubmed" id="17059515" target="_blank">17059515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16278334">
<a name="16278334"></a>Johnson CE, “Stability of Pantoprazole in 0.9% Sodium Chloride Injection in Polypropylene Syringes,” <i>Am J Health Syst Pharm</i>, 2005, 62(22):2410-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16278334/pubmed" id="16278334" target="_blank">16278334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26811504">
<a name="26811504"></a>Jung HK, Lee KJ, Choi MG, et al. Efficacy of DA-9701 (motilitone) in functional dyspepsia compared to pantoprazole: a multicenter, randomized, double-blind, non-inferiority study. <i>J Neurogastroenterol Motil.</i> 2016;22(2):254-263. doi: 10.5056/jnm15178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26811504/pubmed" id="26811504" target="_blank">26811504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kahrilas.2020">
<a name="Kahrilas.2020"></a>Kahrilas PJ. Medical management of gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed May 7, 2020. <a href="https://www.uptodate.com/contents/nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity?search=NSAIDS%20%28including%20aspirin%29&amp;source=search_result&amp;selectedTitle=3~150&amp;usage_type=default&amp;display_rank=3" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18789939">
<a name="18789939"></a>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, “American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,” <i>Gastroenterology</i>, 2008, 135(4):1383-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18789939/pubmed" id="18789939" target="_blank">18789939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25207666">
<a name="25207666"></a>Kallam A, Singla A, Silberstein P. Proton pump induced thrombocytopenia: A case report and review of literature. <i>Platelets</i>. 2015;26(6):598-601. doi:10.3109/09537104.2014.953045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/25207666/pubmed" id="25207666" target="_blank">25207666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34995368">
<a name="34995368"></a>Kanno T, Yuan Y, Tse F, Howden CW, Moayyedi P, Leontiadis GI. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. <i>Cochrane Database Syst Rev</i>. 2022;1(1):CD005415. doi:10.1002/14651858.CD005415.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/34995368/pubmed" id="34995368" target="_blank">34995368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23200977">
<a name="23200977"></a>Kastelein F, Spaander MC, Steyerberg EW, et al; ProBar Study Group. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. <i>Clin Gastroenterol Hepatol</i>. 2013;11(4):382-388. doi: 10.1016/j.cgh.2012.11.014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23200977/pubmed" id="23200977" target="_blank">23200977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23419381">
<a name="23419381"></a>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2013;108(3):308-28; quiz 329. doi:10.1038/ajg.2012.444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23419381/pubmed" id="23419381" target="_blank">23419381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18664620">
<a name="18664620"></a>Kearns GL, Blumer J, Schexnayder S, et al, "Single-Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents," <i>J Clin Pharmacol</i>, 2008, 48(11):1356-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18664620/pubmed" id="18664620" target="_blank">18664620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17014584">
<a name="17014584"></a>Keyvani L, Murthy S, Leeson S, Targownik LE. Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding. <i>Aliment Pharmacol Ther.</i> 2006;24(8):1247-1255. doi:10.1111/j.1365-2036.2006.03115.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17014584/pubmed" id="17014584" target="_blank">17014584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20607405">
<a name="20607405"></a>Kierkus J, Furmaga-Jablonska W, Sullivan JE, et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. <i>Dig Dis Sci</i>. 2011;56:425-434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20607405/pubmed" id="20607405" target="_blank">20607405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29767318">
<a name="29767318"></a>Kim J, Blackett JW, Jodorkovsky D. Strategies for effective discontinuation of proton pump inhibitors. <i>Curr Gastroenterol Rep</i>. 2018;20(6):27. doi: 10.1007/s11894-018-0632-y.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/29767318/pubmed" id="29767318" target="_blank">29767318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23109611">
<a name="23109611"></a>Klassen S, Krepinsky JC, Prebtani AP. Pantoprazole-induced acute interstitial nephritis. <i>CMAJ</i>. 2013;185(1):56-59. doi:10.1503/cmaj.120954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23109611/pubmed" id="23109611" target="_blank">23109611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9623552">
<a name="9623552"></a>Kliem V, Bahlmann J, Hartmann M, Huber R, Lühmann R, Wurst W. Pharmacokinetics of pantoprazole in patients with end-stage renal failure. <i>Nephrol Dial Transplant</i>. 1998;13(5):1189‐1193. doi:10.1093/ndt/13.5.1189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/9623552/pubmed" id="9623552" target="_blank">9623552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32718584">
<a name="32718584"></a>Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations.<i> Therapie.</i> 2020;S0040-5957(20)30127-X. doi:10.1016/j.therap.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/32718584/pubmed" id="32718584" target="_blank">32718584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30354950">
<a name="30354950"></a>Krag M, Marker S, Perner A, et al; SUP-ICU Trial Group. Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. <i>N Engl J Med</i>. 2018;379(23):2199-2208. doi: 10.1056/NEJMoa1714919.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30354950/pubmed" id="30354950" target="_blank">30354950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21626263">
<a name="21626263"></a>Lai HC, Hsu SW, Lu CH, et al. Anaphylaxis to pantoprazole during general anesthesia. <i>J Anesth</i>. 2011;25(4):606-608. doi:10.1007/s00540-011-1148-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21626263/pubmed" id="21626263" target="_blank">21626263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929377">
<a name="33929377"></a>Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. <i>Am J Gastroenterol</i>. 2021;116(5):899-917. doi:10.14309/ajg.0000000000001245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/33929377/pubmed" id="33929377" target="_blank">33929377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22310222">
<a name="22310222"></a>Laine L, Jensen DM. Management of patients with ulcer bleeding. <i>Am J Gastroenterol</i>. 2012;107(3):345-360. doi: 10.1038/ajg.2011.480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22310222/pubmed" id="22310222" target="_blank">22310222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27890768">
<a name="27890768"></a>Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. <i>Gastroenterology</i>. 2017;152(4):821-829.e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/27890768/pubmed" id="27890768" target="_blank">27890768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24327038">
<a name="24327038"></a>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24327038/pubmed" id="24327038" target="_blank">24327038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19240698">
<a name="19240698"></a>Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. <i>Am J Gastroenterol</i>. 2009;104(3):728-738. doi: 10.1038/ajg.2009.115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19240698/pubmed" id="19240698" target="_blank">19240698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32677040">
<a name="32677040"></a>Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al; EUREOS EoE CONNECT research group. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. <i>Aliment Pharmacol Ther</i>. 2020;52(5):798-807. doi:10.1111/apt.15957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/32677040/pubmed" id="32677040" target="_blank">32677040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23746903">
<a name="23746903"></a>Lau JY, Barkun A, Fan DM; Kuipers EJ, Yang YS, Chan FK. Challenges in the management of acute peptic ulcer bleeding. <i>Lancet</i>. 2013;381:2033-2043.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23746903/pubmed" id="23746903" target="_blank">23746903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lazarus.2016">
<a name="Lazarus.2016"></a>Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. <i>JAMA Intern Med</i>. 2016:238-246.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35135340">
<a name="35135340"></a>Leung T, Kedzior S, Moore K, Bierman J, Coralic Z. Intermittent versus continuous infusion dosing of intravenous proton pump inhibitors for upper gastrointestinal bleeding.<i> Ann Pharmacother.</i> 2022;56(10):1127-1132. doi:10.1177/10600280211073936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/35135340/pubmed" id="35135340" target="_blank">35135340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064601">
<a name="22064601"></a>Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” <i>Circulation</i>, 2011, 124(23):e574-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22064601/pubmed" id="22064601" target="_blank">22064601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10734021">
<a name="10734021"></a>Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. <i>Gastroenterology</i>. 2000;118(4):696-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10734021/pubmed" id="10734021" target="_blank">10734021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Li.2004">
<a name="Li.2004"></a>Li X-Q, Anderson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. <i>Drug Metab Disp.</i> 2004;32(8):821-827.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28658503">
<a name="28658503"></a>Lin CY, Wang CW, Hui CR, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. <i>Allergy</i>. 2018;73(1):221-229. doi:10.1111/all.13235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28658503/pubmed" id="28658503" target="_blank">28658503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629618">
<a name="23629618"></a>Lightdale JR, Gremse DA, Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: Management guidance for the pediatrician. <i>Pediatrics.</i> 2013;131(5):e1684-e1695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23629618/pubmed" id="23629618" target="_blank">23629618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Longstreth.2020">
<a name="Longstreth.2020"></a>Longstreth GF, Lacy BE. Approach to the adult with dyspepsia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 20, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26247167">
<a name="26247167"></a>Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2016;14(1):13-22.e1. doi:10.1016/j.cgh.2015.07.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26247167/pubmed" id="26247167" target="_blank">26247167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058466">
<a name="32058466"></a>Lyu B, Jorgenson MR, Hansen KE, Djamali A, Astor BC. Proton pump inhibitors, but not H2-receptor antagonists, are associated with incident fractures among kidney transplant recipients. <i>Transplantation</i>. 2020;104(12):2609-2615. doi:10.1097/TP.0000000000003178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/32058466/pubmed" id="32058466" target="_blank">32058466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12548064">
<a name="12548064"></a>Madrazo-de la Garza A, Dibildox M, Vargas A, et al. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. <i>J Pediatr Gastroenterol Nutr.</i> 2003;36(2):261-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/12548064/pubmed" id="12548064" target="_blank">12548064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31175146">
<a name="31175146"></a>Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E. Early acid suppression therapy exposure and fracture in young children. <i>Pediatrics</i>. 2019;144(1):e20182625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/31175146/pubmed" id="31175146" target="_blank">31175146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20378675">
<a name="20378675"></a>Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. <i>QJM</i>. 2010;103(6):387-395. doi:10.1093/qjmed/hcq021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20378675/pubmed" id="20378675" target="_blank">20378675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14570652">
<a name="14570652"></a>Memiş D, Turan A, Karamanlioglu B, Saral P, Türe M, Pamukçu Z. The effect of intravenous pantoprazole and ranitidine for improving preoperative gastric fluid properties in adults undergoing elective surgery. <i>Anesth Analg</i>. 2003;97(5):1360-1363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/14570652/pubmed" id="14570652" target="_blank">14570652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16423003">
<a name="16423003"></a>Metz DC, Comer GM, Soffer E, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. <i>Aliment Pharmacol Ther</i>. 2006;23(3):437-444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16423003/pubmed" id="16423003" target="_blank">16423003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11774936">
<a name="11774936"></a>Metz DC, Forsmark C, Lew EA, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. <i>Am J Gastroenterol.</i> 2001;96(12):3274-3280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/11774936/pubmed" id="11774936" target="_blank">11774936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10710049">
<a name="10710049"></a>Metz DC, Pratha V, Martin P, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2000;95(3):626-633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10710049/pubmed" id="10710049" target="_blank">10710049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29532602">
<a name="29532602"></a>Meunier L, Ursic-Bedoya J, Pageaux GP, Larrey D. Pantoprazole-induced autoimmune chronic hepatitis. <i>Liver Int</i>. 2018;38(6):995-999. doi:10.1111/liv.13737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/29532602/pubmed" id="29532602" target="_blank">29532602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28631728">
<a name="28631728"></a>Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28631728/pubmed" id="28631728" target="_blank">28631728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31152740">
<a name="31152740"></a>Moayyedi P, Eikelboom JW, Bosch J, et al; COMPASS Investigators. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. <i>Gastroenterology</i>. 2019;157(3):682-691.e2. doi:10.1053/j.gastro.2019.05.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/31152740/pubmed" id="31152740" target="_blank">31152740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17805350">
<a name="17805350"></a>Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. <i>J Invest Dermatol</i>. 2008;128(1):35-44. doi:10.1038/sj.jid.5701033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17805350/pubmed" id="17805350" target="_blank">17805350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24927897">
<a name="24927897"></a>Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. <i>Am J Kidney Dis</i>. 2014;64(4):558-566. doi:10.1053/j.ajkd.2014.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24927897/pubmed" id="24927897" target="_blank">24927897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30237993">
<a name="30237993"></a>Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: An updated systematic review and meta-analysis. <i>J Bone Metab</i>. 2018;25(3):141-151. doi:10.11005/jbm.2018.25.3.141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30237993/pubmed" id="30237993" target="_blank">30237993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: Diagnosis and management. Clinical guideline 183. Published September 3, 2014. Updated November 2018. https://www.nice.org.uk/guidance/cg183.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837071">
<a name="19837071"></a>Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. <i>Gastroenterology</i>. 2010;138(1):82-88. doi: 10.1053/j.gastro.2009.09.063.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19837071/pubmed" id="19837071" target="_blank">19837071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25112692">
<a name="25112692"></a>Nylund CM, Eide M, Gorman GH. Association of Clostridium difficile infections with acid suppression medications in children. <i>J Pediatr</i>. 2014;165(5):979-984.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/25112692/pubmed" id="25112692" target="_blank">25112692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31187275">
<a name="31187275"></a>Park YH, Seong JM, Cho S, et al. Effects of proton pump inhibitor use on risk of <i>Clostridium difficile</i> infection: a hospital cohort study. <i>J Gastroenterol</i>. 2019;54(12):1052-1060. doi:10.1007/s00535-019-01598-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/31187275/pubmed" id="31187275" target="_blank">31187275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37269915">
<a name="37269915"></a>Peron A, Ripoche E, Picot C, Ajiji P, Cucherat M, Cottin J. Use of proton pump inhibitors during pregnancy: a systematic review and meta-analysis of congenital malformations. <i>Reprod Toxicol</i>. 2023;119:108419. doi:10.1016/j.reprotox.2023.108419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/37269915/pubmed" id="37269915" target="_blank">37269915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Petterson.2005">
<a name="Petterson.2005"></a>Petterson G, Faure C, Litalien C, et al. Therapeutic failure of a single intravenous dose of pantoprazole in young intensive care children. <i>Crit Care Med</i>. 2005;33(12): A170.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19173681">
<a name="19173681"></a>Pettersen G, Mouksassi MS, Theoret Y, et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. <i>Br J Clin Pharmacol</i>. 2009;67(2):216-227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19173681/pubmed" id="19173681" target="_blank">19173681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26939578">
<a name="26939578"></a>Philpott H, Nandurkar S, Royce SG, Thien F, Gibson PR. A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis. <i>Aliment Pharmacol Ther</i>. 2016;43(9):985-993. doi:10.1111/apt.13576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26939578/pubmed" id="26939578" target="_blank">26939578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28271513">
<a name="28271513"></a>Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia.<i> Cochrane Database Syst Rev.</i> 2017;3:CD011194. doi: 10.1002/14651858.CD011194.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28271513/pubmed" id="28271513" target="_blank">28271513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18754096">
<a name="18754096"></a>Pisegna JR, Karlstadt RG, Norton JA, et al. Effect of preoperative intravenous pantoprazole in elective-surgery patients: a pilot study. <i>Dig Dis Sci.</i> 2009;54(5):1041-1049. doi: 10.1007/s10620-008-0445-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18754096/pubmed" id="18754096" target="_blank">18754096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15568407">
<a name="15568407"></a>Plante L, Ferron GM, Unruh M, et al, "Excretion of Pantoprazole in Human Breast," <i>J Reprod Med</i>, 2004, 49(10):825-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/15568407/pubmed" id="15568407" target="_blank">15568407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28325163">
<a name="28325163"></a>Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. <i>Epidemiol Infect</i>. 2017;145(8):1617-1623. doi:10.1017/S0950268817000528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28325163/pubmed" id="28325163" target="_blank">28325163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wyeth.1">
<a name="Wyeth.1"></a>Protonix Oral (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wyeth.1">
<a name="Wyeth.1"></a>Protonix Oral (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wyeth.2">
<a name="Wyeth.2"></a>Protonix IV (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wyeth.2">
<a name="Wyeth.2"></a>Protonix IV (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BCMH.2015">
<a name="BCMH.2015"></a>Province of British Columbia Ministry of Health. Proton pump inhibitors in primary care. BC Provincial Academic Detailing (PAD) Service. Published January 2015. Accessed November 11, 2019. <a href="https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/provincial-academic-detailing-service/pad-2015-proton-pump-inhibitors-newsletter.pdf" target="_blank">https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/provincial-academic-detailing-service/pad-2015-proton-pump-inhibitors-newsletter.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22289674">
<a name="22289674"></a>Puig I, Calzado S, Suárez D, Sánchez-Delgado J, López S, Calvet X. Meta-analysis: comparative efficacy of H2-receptor antagonists and proton pump inhibitors for reducing aspiration risk during anesthesia depending on the administration route and schedule. <i>Pharmacol Res</i>. 2012;65(4):480-490. doi: 10.1016/j.phrs.2012.01.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22289674/pubmed" id="22289674" target="_blank">22289674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610598">
<a name="29610598"></a>Qorraj-Bytyqi H, Hoxha R, Sadiku S, et al. Proton pump inhibitors intake and iron and vitamin B12 status: A prospective comparative study with a follow up of 12 months. <i>Open Access Maced J Med Sci</i>. 2018;6(3):442-446. doi:10.3889/oamjms.2018.142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/29610598/pubmed" id="29610598" target="_blank">29610598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21930865">
<a name="21930865"></a>Quasdorff M, Mertens J, Dinter J, Steffen HM. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. <i>Ann Intern Med</i>. 2011;155(6):405-407. doi:10.7326/0003-4819-155-6-201109200-00022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21930865/pubmed" id="21930865" target="_blank">21930865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12095478">
<a name="12095478"></a>Ramakrishnan A, Katz PO. Pharmacologic management of gastroesophageal reflux disease. <i>Curr Treat Options Gastroenterol</i>. 2002;5(4):301-310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/12095478/pubmed" id="12095478" target="_blank">12095478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12070410">
<a name="12070410"></a>Ramdani A, Mignon M, Samoyeau R. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. <i>Gastroenterol Clin Biol</i>. 2002;26(4):355-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/12070410/pubmed" id="12070410" target="_blank">12070410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16817839">
<a name="16817839"></a>Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. <i>Am J Gastroenterol</i>. 2006;101(8):1747-1755.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16817839/pubmed" id="16817839" target="_blank">16817839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8527617">
<a name="8527617"></a>Rehner M, Rohner HG, Schepp W. Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study. <i>Aliment Pharmacol Ther</i>. 1995;9(4):411-416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/8527617/pubmed" id="8527617" target="_blank">8527617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016.<i> Intensive Care Med.</i> 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30792587">
<a name="30792587"></a>Ribeiro RHT, Ribeiro FA, Silva RPM, Bortolini MJS, Garrote-Filho MDS, Penha-Silva N. Depression, hematologic parameters, and blood levels of vitamin B<sub>12</sub> in patients with <i>Laryngopharyngeal</i> reflux under use of proton pump inhibitors. <i>Clin Med Insights Ear Nose Throat</i>. 2019;12:1179550619828683. doi:10.1177/1179550619828683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30792587/pubmed" id="30792587" target="_blank">30792587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19255077">
<a name="19255077"></a>Ricketson J, Kimel G, Spence J, Weir R. Acute allergic interstitial nephritis after use of pantoprazole. <i>CMAJ</i>. 2009;180(5):535-538. doi:10.1503/cmaj.080456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19255077/pubmed" id="19255077" target="_blank">19255077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30051945">
<a name="30051945"></a>Rodríguez-Martín S, Martín-Merino E, Lerma V, et al. Active surveillance of severe cutaneous adverse reactions: A case-population approach using a registry and a health care database. <i>Pharmacoepidemiol Drug Saf</i>. 2018;27(9):1042-1050. doi:10.1002/pds.4622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30051945/pubmed" id="30051945" target="_blank">30051945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470322">
<a name="29470322"></a>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(3):516-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/29470322/pubmed" id="29470322" target="_blank">29470322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Saltzman.2020">
<a name="Saltzman.2020"></a>Saltzman JR. Overview of the treatment of bleeding peptic ulcers. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23960351">
<a name="23960351"></a>Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute interstitial nephritis due to proton pump inhibitors. <i>Indian J Nephrol</i>. 2013;23(4):304-307. doi:10.4103/0971-4065.114487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23960351/pubmed" id="23960351" target="_blank">23960351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24547721">
<a name="24547721"></a>Sandholdt LH, Laurinaviciene R, Bygum A. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. <i>Br J Dermatol</i>. 2014;170(2):342-351. doi:10.1111/bjd.12699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24547721/pubmed" id="24547721" target="_blank">24547721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21298607">
<a name="21298607"></a>Sandig C, Flechtenmacher C, Stremmel W, Eisenbach C. Pantoprazole induces severe acute hepatitis. <i>Z Gastroenterol</i>. 2011;49(2):207-210. doi:10.1055/s-0029-1245613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21298607/pubmed" id="21298607" target="_blank">21298607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9882033">
<a name="9882033"></a>Savarino V, Mela GS, Zentilin P, et al. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer.<i> Aliment Pharmacol Ther</i>. 1998;12(12):1241-1247.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/9882033/pubmed" id="9882033" target="_blank">9882033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29894542">
<a name="29894542"></a>Schmitz B, Sorrells T, Glass JS. Acute generalized exanthematous pustulosis caused by pantoprazole. <i>Cutis</i>. 2018;101(5):E22-E23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/29894542/pubmed" id="29894542" target="_blank">29894542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27635481">
<a name="27635481"></a>Selvanderan SP, Summers MJ, Finnis ME, et al. Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. <i>Crit Care Med</i>. 2016;44(10):1842-1850. doi: 10.1097/CCM.0000000000001819.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/27635481/pubmed" id="27635481" target="_blank">27635481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26526079">
<a name="26526079"></a>Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett's esophagus [published correction appears in <i>Am J Gastroenterol</i>. 2016;111(7):1077]. <i>Am J Gastroenterol</i>. 2016;111(1):30-50. doi: 10.1038/ajg.2015.322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26526079/pubmed" id="26526079" target="_blank">26526079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30257076">
<a name="30257076"></a>Shakhnovich V, Abdel-Rahman S, Friesen CA, et al. Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity [published online September 26, 2018]. <i>Pediatr Obes</i>. 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30257076/pubmed" id="30257076" target="_blank">30257076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29389444">
<a name="29389444"></a>Shakhnovich V, Smith PB, Guptill JT, et al. Obese children require lower doses of pantoprazole than nonobese peers to achieve equal systemic drug exposures. <i>J Pediatr</i>. 2018;193:102-108.e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/29389444/pubmed" id="29389444" target="_blank">29389444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21365243">
<a name="21365243"></a>Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. <i>Dig Dis Sci</i>. 2011;56(4):931-950. doi:10.1007/s10620-010-1560-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21365243/pubmed" id="21365243" target="_blank">21365243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19350116">
<a name="19350116"></a>Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. <i>Thromb Haemost</i>. 2009;101(4):714-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19350116/pubmed" id="19350116" target="_blank">19350116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17014549">
<a name="17014549"></a>Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. <i>Nephrology (Carlton)</i>. 2006;11(5):381-385. doi:10.1111/j.1440-1797.2006.00651.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17014549/pubmed" id="17014549" target="_blank">17014549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spechler2019">
<a name="Spechler2019"></a>Spechler S. Barrett's esophagus: surveillance and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/barretts-esophagus-surveillance-and-management?search=barrett&amp;source=search_result&amp;selectedTitle=1~78&amp;usage_type=default&amp;display_rank=1#H62054350" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16443807">
<a name="16443807"></a>Spirt MJ, Stanley S. Update on stress ulcer prophylaxis in critically ill patients. <i>Crit Care Nurse</i>. 2006;26:18-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16443807/pubmed" id="16443807" target="_blank">16443807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30910853">
<a name="30910853"></a>Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. <i>BMJ</i>. 2019;364:l536. doi:10.1136/bmj.l536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30910853/pubmed" id="30910853" target="_blank">30910853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19221370">
<a name="19221370"></a>Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: A randomized trial. <i>Ann Intern Med.</i> 2009;150(7):455-464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19221370/pubmed" id="19221370" target="_blank">19221370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19949136">
<a name="19949136"></a>Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. <i>Ann Intern Med</i>. 2010;152(1):1-9. doi:10.7326/0003-4819-152-1-201001050-00179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19949136/pubmed" id="19949136" target="_blank">19949136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21740077">
<a name="21740077"></a>Tammara BK, Sullivan JE, Adcock KG, et al. Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through &lt;6 years with gastro-oesophageal reflux disease. <i>Clin Pharmacokinet.</i> 2011;50(8):541-550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21740077/pubmed" id="21740077" target="_blank">21740077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18695179">
<a name="18695179"></a>Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. <i>CMAJ</i>. 2008;179(4):319-326. doi:10.1503/cmaj.071330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18695179/pubmed" id="18695179" target="_blank">18695179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626024">
<a name="9626024"></a>Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. <i>Am J Med</i>. 1998;104(5):422-430. doi:10.1016/s0002-9343(98)00087-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/9626024/pubmed" id="9626024" target="_blank">9626024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31950535">
<a name="31950535"></a>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. <i>Aliment Pharmacol Ther</i>. 2020;51(4):421-434. doi:10.1111/apt.15611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/31950535/pubmed" id="31950535" target="_blank">31950535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31060319">
<a name="31060319"></a>Thong BKS, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: A review of current evidence and mechanisms involved. <i>Int J Environ Res Public Health</i>. 2019;16(9):1571. doi:10.3390/ijerph16091571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/31060319/pubmed" id="31060319" target="_blank">31060319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16641576">
<a name="16641576"></a>Tolia V, Bishop PR, Tsou VM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. <i>J Pediatr Gastroenterol Nutr.</i> 2006;42(4):384-391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16641576/pubmed" id="16641576" target="_blank">16641576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16968960">
<a name="16968960"></a>Tsou VM, Baker R, Book L, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). <i>Clin Pediatr.</i> 2006;45(8):741-749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16968960/pubmed" id="16968960" target="_blank">16968960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047577">
<a name="20047577"></a>Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. <i>Aliment Pharmacol Ther</i>. 2010;31(7):754-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20047577/pubmed" id="20047577" target="_blank">20047577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.2020a">
<a name="Vakil.2020a"></a>Vakil NB. Approach to refractory or recurrent peptic ulcer disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed May 7, 2020a. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.2020b">
<a name="Vakil.2020b"></a>Vakil NB. Overview of complications of peptic ulcer disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed October 23, 2020b. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.2019">
<a name="Vakil.2019"></a>Vakil NB. Peptic ulcer disease: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed November 11, 2019. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.1">
<a name="Vakil.1"></a>Vakil NB. Peptic ulcer disease: treatment and secondary prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30262672">
<a name="30262672"></a>Vangala C, Niu J, Lenihan CR, Mitch WE, Navaneethan SD, Winkelmayer WC. Proton pump inhibitors, histamine-2 receptor antagonists, and hip fracture risk among patients on hemodialysis. <i>Clin J Am Soc Nephrol</i>. 2018;13(10):1534-1541. doi:10.2215/CJN.02190218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/30262672/pubmed" id="30262672" target="_blank">30262672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18534050">
<a name="18534050"></a>van Rensburg C, Berghöfer P, Enns R, et al. Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. <i>Curr Med Res Opin.</i> 2008;24(7):2009-2018. doi: 10.1185/03007990802184545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18534050/pubmed" id="18534050" target="_blank">18534050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117619">
<a name="24117619"></a>Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, Devault KR, Talley NJ, Achem SR. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. <i>Aliment Pharmacol Ther</i>. 2013;38(10):1312-1319. doi:10.1111/apt.12513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24117619/pubmed" id="24117619" target="_blank">24117619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26956016">
<a name="26956016"></a>Verhaegh BP, de Vries F, Masclee AA, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. <i>Aliment Pharmacol Ther</i>. 2016;43(9):1004-1013. doi:10.1111/apt.13583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26956016/pubmed" id="26956016" target="_blank">26956016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32176276">
<a name="32176276"></a>Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association between proton pump inhibitor use and risk of fracture in children [published online March 16, 2020]. <i>JAMA Pediatr</i>. 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/32176276/pubmed" id="32176276" target="_blank">32176276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19373423">
<a name="19373423"></a>Wang J, Yang K, Ma B, et al. Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. <i>Can J</i>
<i>Gastroenterol</i>. 2009;23(4):287-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19373423/pubmed" id="19373423" target="_blank">19373423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20852004">
<a name="20852004"></a>Ward RM, Kearns GL, Tammara B, et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with GERD. <i>J Clin Pharmacol</i>. 2011;51(6):876-887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20852004/pubmed" id="20852004" target="_blank">20852004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20306184">
<a name="20306184"></a>Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). <i>Eur J Clin Pharmacol</i>. 2010;66:555-561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20306184/pubmed" id="20306184" target="_blank">20306184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16569810">
<a name="16569810"></a>Watson TD, Stark JE, Vesta KS. Pantoprazole-induced thrombocytopenia.<i> Ann Pharmacother</i>. 2006;40(4):758-761. doi:10.1345/aph.1G384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16569810/pubmed" id="16569810" target="_blank">16569810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28054368">
<a name="28054368"></a>Wei L, Ratnayake L, Phillips G, et al. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. <i>Br J Clin Pharmacol</i>. 2017;83(6):1298-1308. doi:10.1111/bcp.13205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28054368/pubmed" id="28054368" target="_blank">28054368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weinhouse.1">
<a name="Weinhouse.1"></a>Weinhouse GL. Stress ulcers in the intensive care unit: diagnosis, management, and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19561850">
<a name="19561850"></a>Wensel TM. Administration of proton pump inhibitors in patients requiring enteral nutrition. <i>P T</i>. 2009;34(3):143-160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19561850/pubmed" id="19561850" target="_blank">19561850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20400912">
<a name="20400912"></a>Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. <i>J Pediatr Gastroenterol Nutr.</i> 2010;50(6):609-618.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20400912/pubmed" id="20400912" target="_blank">20400912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7766739">
<a name="7766739"></a>Witzel L, Gütz H, Hüttemann W, Schepp W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. <i>Aliment Pharmacol Ther.</i> 1995;9(1):19-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/7766739/pubmed" id="7766739" target="_blank">7766739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wolfe.2020">
<a name="Wolfe.2020"></a>Wolfe MM. Proton pump inhibitors: overview of use and adverse effects in the treatment of acid related disorders. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed May 7, 2020. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10868896">
<a name="10868896"></a>Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. <i>Gastroenterology</i>. 2000;118(2)(suppl 1):9-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10868896/pubmed" id="10868896" target="_blank">10868896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22550833">
<a name="22550833"></a>Yamada S, Wongwanakul P. Randomized controlled trial of high dose bolus versus continuous intravenous infusion pantoprazole as an adjunct therapy to therapeutic endoscopy in massive bleeding peptic ulcer. <i>J Med Assoc Thai</i>. 2012;95(3):349-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22550833/pubmed" id="22550833" target="_blank">22550833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17190895">
<a name="17190895"></a>Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. <i>JAMA</i>. 2006;296(24):2947-2953.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17190895/pubmed" id="17190895" target="_blank">17190895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10677134">
<a name="10677134"></a>Yusoff IF, Nairn P, Morgan CA. Multiple organ failure related to pantoprazole. <i>Aust N Z J Med</i>. 1999;29(6):833-834. doi:10.1111/j.1445-5994.1999.tb00796.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10677134/pubmed" id="10677134" target="_blank">10677134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677158">
<a name="16677158"></a>Zargar SA, Javid G, Khan BA, et al. Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial. <i>J Gastroenterol Hepatol</i>. 2006;21(4):716-721. doi:10.1111/j.1440-1746.2006.04292.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16677158/pubmed" id="16677158" target="_blank">16677158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29676433">
<a name="29676433"></a>Zirk-Sadowski J, Masoli JA, Delgado J, et al. Proton-pump inhibitors and long-term risk of community-acquired pneumonia in older adults. <i>J Am Geriatr Soc</i>. 2018;66(7):1332-1338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/29676433/pubmed" id="29676433" target="_blank">29676433</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9474 Version 786.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
